Deanna L. Kelly, PharmD, BCPP

Peer Reviewed Book Chapters

1. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia. Professional Communications, Inc. First Edition, Caddo, OK 2000.
2. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia.  Professional Communications, Inc. Second Edition, Caddo, OK 2003.
3. Conley RR, Kelly DL. Pharmacologic treatment of schizophrenia.  Professional Communications, Inc. Third Edition, Caddo, OK, 2007.
4. Conley RR, Kelly DL. The long-term efficacy, effectiveness and safety of second-generation antipsychotic drugs. In: Atypical antipsychotics: from bench to bedside. Editors: Csernansky JG, Lauriello J.  Marcel Dekker 2004.
5. Conley RR, Kelly DL. Schizophrenia.  In Conn’s Current Therapy 2005.  Editors:  Rakel R and Bope E. Philadelphia, PA: W.B. Saunders, Philadelphia 2005, pp. 1280-1284.
6. Conley RR, Kelly DL. Schizophrenia. In Conn’s Current Therapy 2006. Editors: Rakel R and Bope E. Philadelphia, PA:  W. B. Saunders, Philadelphia 2006, 1370-1374.
7. Boggs D, Kelly DL, Conley RR. Antipsychotic Therapeutics (Efficacy and Side Effects). In The Year in SchizophreniaVolumeI. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK.  2007,209-231.
8. Kelly DL, Weiner E. Schizophrenia, in Pharmacotherapy Principles and Practice, Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2008.
9. Kelly DL, Boggs DL, Conley RR. Reaching for wellness in schizophrenia:  A Complex Disease Necessitating Complex Care. Psychiatric Clinics of North America, Buckley PF, Messias EL (eds), Saunders, Philadelphia, PA 2007;30:453-479.
10. Boggs D, Kelly DL. Antipsychotic Therapeutics. In The Year in Schizophrenia Volume II. Editors: Thaker G, Carpenter WT., Clinical Publishing, Oxford, UK.  2008.
11. Wehring HJ, Kelly DL. Sexual Dysfunction in Schizophrenia. In: Medical Illness in Schizophrenia, second edition 2009. Eds Meyer JM, Nasrallah HA. American Psychiatric Publishing, Inc.
12. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, second edition. Chisholm-Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2010.
13. Perez G, Dixon L, Kelly DL. Evidence Based Medicine. In: Levin BL, Becker MA (Eds.). A Public Health Perspective of Women's Mental Health. New York: Springer, 2010.
14. Kelly DL, Buchanan RW. Clozapine: It’s Current Status In and Beyond Treatment Resistant Schizophrenia. In: Therapeutic Strategies in Schizophrenia. 2010. Eds., P McKenna, A. Mortimer. Clinical Publishing Limited.
15. Wehring HJ, Kelly DL. Schizophrenia. In; Pharmacotherapy Principles & Practice Study Guide:  A Cased Based Care Plan Approach, First Edition.  Michael D. Katz, Kathryn R. Matthias, and Marie A. Chisholm-Burns, Editors. The McGraw-Hill Companies, Inc. 2010.
16. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, third edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2012
17. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, third edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2014
18. Kelly DL, Weiner E, Wehring H. Schizophrenia, in Pharmacotherapy Principles and Practice, fourth edition, Chrisholm, Burns M, Wells BG, Schwinghammer TL, et al (eds), McGraw-Hill, New York, New York, 2016.

Peer-reviewed journal articles

1. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates of depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. American Journal of Health-Systems Pharmacy. 1998;55(4):17-19. PMID: 987268.
2. Sherr JD, Kelly DL.  Substitution of immediate release valproic acid for divalproex sodium for adult psychiatric inpatients.  Psychiatric Services. 1998;49:1355-57. PMID: 9779912.
3. Conley, RR, Kelly DL, Gale E. Olanzapine response in therapy-refractory schizophrenia with substance abuse.  Schizophrenia Research. 1998;33:95-101. PMID: 9783349.
4. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM.  Weight gain in adolescents treated with risperidone and conventional antipsychotics. The Journal of the Child and Adolescent Psychopharmacology. 1998;8:151-159. PMID: 9853689.
5. Kelly DL, Conley RR, Tamminga CA.   Differential olanzapine plasma concentrations by sex in a fixed dose study. Schizophrenia Research. 1999;40(2):101-4. PMID: 10593449.
6. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry. 1999;156:863-868. PMID:10360124.
7. Conley RR, Tamminga CA, Kelly DL, Richardson C. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.  Biological Psychiatry. 1999; 46;73-77. PMID:10394475.
8. Love RC, Conley RR, Kelly DL, Bartko JJ. A dose-outcome analysis of risperidone. J Clin Psychiatry. 1999;60:771-775. PMID: 10584767.
9. Kelly DL, Love RC. Ziprasidone and the QTc: pharmacokinetic and pharmacodynamic considerations. Psychopharmacology Bulletin. 2001;35:66-79. PMID: 12397857.
10. Richardson C, Kelly DL, Conley RR. Biperiden for excessive sweating associated with clozapine use. Am J Psychiatry. 2001;158:1329-30. PMID: 11481174.
11. Conley RC, Kelly DL. Management of treatment-resistant schizophrenia. Biological Psychiatry. 2001;50:898-911.PMID: 11743944.
12. Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.  Psychiatric Services. 2001;52:676-8. PMID: 11331805.
13. Conley RR, Kelly DL. Current status of antipsychotic treatment. Current Drug Targets - CNS and Neurological Disorders. 2002;1:123-128. PMID:12769630.
14. Kreyenbuhl J, Kelly DL, Conley RR.  Circumstances of suicide among patients with schizophrenia. Schizophrenia Research. 2002;58(2-3):253-6. PMID: 12409166.
15. McMahon RP, Kelly DL Kreyenbuhl J, Kirkpatrick B, Love RC, Conley RR. Novel factor-based symptom scores in treatment-resistant schizophrenia: implications for clinical trials. Neuropsychopharmacology. 2002;537-545. PMID: 11927178.
16. Kelly DL, Conley RR, Richardson CM, TammingaCA, Carpenter WT Jr. Adverse Effects and Laboratory Parameters of High-Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia. Annals of Clin Psychiatry. 2003;15:181-6. PMID: 14971863.
17. Kelly DL, Kreyenbuhl J, Love RC, Van-Duong Q, Conley RR. Six-month review of weight and metabolic parameters in patients on clozapine, risperidone, olanzapine and quetiapine. Journal of Clinical Psychiatry. 2003;64:1133-4. PMID: 14628994.
18. Kelly DL, Gale EA, Yu Y, Conley RR. Clozapine treatment in patients with prior substance abuse. Canadian Journal of Psychiatry. 2003;48(2):111-4.
19. Kelly DL, Conley RR. Evaluating sexual function in patients with treatment-resistant schizophrenia.  Schizophrenia Research. 2003;63(1-2):195-6. PMID: 12892874.
20. Wehring H, Kelly DL, Love RC, Conley RR. Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry. 2003;160:2241-2242. PMID:14638600.
21. Lambert TJR, Cock N, Alcock S, Kelly DL, Conley RR. Measurement of antipsychotic-induced side effects: Support for the validity of a self-report (LUNSERS) vs. structured interview (UKU) approach to measurement. Human Psychopharmacology. 2003;18(5):405-41. PMID:12858330.
22. Nelson M, Reynolds R, Kelly DL, Conley RR. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone: case report. Clinical Neuropharmacology. 2003;26:297-8. PMID: 14646608.
23. Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Annals of Clinical Psychiatry. 2003. 15:23-31. PMID:12839430.
24. Conley RR, Kelly DL, Richardson CM, TammingaCA, Carpenter WT Jr.  The Efficacy of High Dose Olanzapine vs. Clozapine in Treatment-Resistant Schizophrenia: A Double-Blind Crossover Study.  J Clin Psychopharmacology. 2003;23:668-671. PMID: 14624201.
25. Lambert TJ, Brenan A, Castle DJ, Kelly DL, Conley RR. Perception of depot antipsychotics by mental health professionals. J Psychiatric Practice. 2003;9(3):252-260. PMID: 15985940.
26. Love RC, Kelly DL. Olanzapine and risperidone. American Journal of Health-Systems Pharmacy. 2003;60:487-88. PMID: 12635459.
27. Shim J-C, Kelly DL, Kim Y-H, Yoon Y-R, Park JH, Shin J-G, Conley RR. Fluoxetine augmentation of haloperidol in chronic schizophrenia. J Clin Psychopharmacology. 2003; 520-2. PMID:14520132
28. Lambert, TJ, Kelly DL, Alcock S, Conley RR. Psychotropic prescribing for acute inpatient admissions in patients with severe psychosis. J Clin Psychopharmacology. 2004;24:91-3. PMID: 14709954
29. Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophrenia Bulletin: 2004;30:767-779. PMID:15954189
30. Kelly DL, Shim J-C, Feldman SM, Yu Y, Conley RR. Lifetime Psychiatric Symptoms in Persons with Schizophrenia Who Died by Suicide Compared to Other Means of Death. J of Psychiatric Research. 2004;38:531-36. PMID:15380404
31. Kelly DL, Love RC, Mackowick M, Conley RR. Atypical Antipsychotic Use in a StateHospital Inpatient Adolescent Population, Journal of Child and Adolesc Psychopharmacology. 2004; 14(1):75-85. PMID:15142394
32. Conley RR, Kelly DL, Beason-Held, Holcomb H, Richardson C, Tamminga CA, Carpenter WT. The effects of clozapine and high dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. Journal of Psychopharmacology. 2004;18:429-31. PMID:15358989
33. Kim YH,Shim J-C, Kelly DL, Lee J-G, Seo Y-S, Conley RR. Cortisol Response to Buspirone in Extended Abstinent Alcoholics. Alcohol and Alcoholism. 2004;39(4):287-289. PMID:15208158
34. Conley RR, Shim JC, Kelly DL, Yu Y, Feldman S, McMahon RP. Cardiovascular disease in Relation to Weight in deceased persons with schizophrenia. Comprehensive Psychiatry. 2005;46:460-7. PMID:16275214
35. Conley RR, Kelly DL.  Review of Current Drug Targets and Pharmacology of Antipsychotic Treatment. Medicinal Chemistry Reviews- Online. 2005;2(3):177-182.
36. Jung DU, Seo YS, Park JH, Jeong CY, Conley RR, Kelly DL, Shim JC. The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. J Clin Psychopharmacol 2005;25:613-615, PMID:16282852.
37. Kelly DL. The Schizophrenic Patient: The Reproductive Years and Beyond The Female Patient, OB-GYN edition, 2005;30(8):22-31.
38. Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Israel Journal of Psychiatr and Related Sciences. 2005;42(1):51-60. PMID:16134407
39. Conley RR, Kelly DL, Nelson M, Richardson CM, Feldman S, Reynolds R, Steiner P, Yu Y, Khan I, McMullen R, Gale E, Mackowick M, Love R. Risperidone and quetiapine vs. fluphenazine in treatment-resistant schizophrenia. Clinical Neuropharmacology. 2005;28(4):163-8. PMID:16062094
40. Kelly DL, Carpenter WT, Conley RR. First Episode Schizophrenia: A Focus on Pharmacologic Treatment and Safety Considerations. Drugs. 2005; 65:1113-38. PMID:15907146
41. Conley RR, Kelly DL, Lambert TJ, Love RC. A comparison of clozapine use in Maryland and in Victoria, Australia. Psychiatric Services. 2005;56:320-3. PMID:15746507
42. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone or fluphenazine. Journal of Clinical Psychiatry. 2005;66:80-84. PMID:15669892
43. Shim J-C Kim Y-H, Kelly DL, Lee J-G, Conley RR. Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia.  Journal of Neuropsychiatry and Clinical Neurosciences. 2005;17:221-6. PMID:15939977
44. Kelly DL. Treatment Considerations in Women with Schizophrenia. Journal of Women’s Health. 2006;15:1132-40.  PMID:17199454
45. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine Underutilization and Discontinuation in African-Americans Due to Leucopenia. Schizophrenia Bulletin. 2007;33(5):1221-4. PMID:17170061 
46. Kelly DL, Dixon L, Kreyenbuhl J, Lehman AF, Love RC, Medoff D, Brown C, Conley RR. Clozapine Utilization and Outcomes by Race in a Public Mental Health System: 1994-2000. J Clin Psychiatry. 2006;67:1404-11. PMID:17017827
47. Jung D-O, Conley RR, Kelly DL, Kim D_W, Yoon S-H, Jang J-H, Shin J-G, Shim J-C. The Prevalence of Bone Mineral Density Loss in the Korean Patients with Chronic Schizophrenia. J Clin Psychiatry. 2006;67:1391-96. PMID:17017825
48. Kelly DL, Richardson CM, Yu Yang, Conley RR. Plasma Concentrations of High Dose Olanzapine in a Double Blind Crossover Study. Human Psychopharmacology: Clinical and Experimental. 2006;21:393-8. PMID:16850522
49. Kelly DL, Conley RR, Feldman S, Yu Y, McMahon RP, Richardson CM. Adjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia. Psychiatric Quarterly. 2006;77(1):81-95. PMID:16397757
50. Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006;31;340-346. PMID:16198059
51. Shim J-C, Shin J-G, Kelly DL, Jung D-U, Seo Y-S, Liu KH, Sohn J-H, Conley RR. Adjunctive Treatment With a Dopamine Partial Agonist, Aripiprazole, for Antipsychotic-Induced Hyperprolactinemia: A Placebo-Controlled Trial. American Journal of Psychiatry. 2007;164 (9):1310-2. PMID:17728426
52. Conley RR, Kelly DL. Clinical Pharmacology and Medication-Associated Side Effects: A Review of Second-Generation Antipsychotics for Schizophrenia. Clinical Schizophrenia & Related Psychoses. 2007;3:135-146.
53. Shim JC, Choe BM, Kim JG, Jae YM, Kim HC, Kim SG, Oh MK,Kelly DL, Conley RR.Discontinuation of Risperidone, Olanzapine, and Haloperidol in First Episode Psychosis. J Clin Psychopharmacol. 2007;27:400-401. PMID:17632229
54. Kelly DL, Kreyenbuhl J, Buchanan RW, Malhotra MK. Why Not Clozapine? Clinical Schizophrenia & Related Psychoses. 2007;1:92-5.
55. Conley RR, Kelly DL. Drug–drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients. Psychopharmacology Bulletin. 2007;40:77-97. PMID:17285099
56. Kelly, DL, Conley RR, Love RC, Morrison JA, McMahon RP. Metabolic Risk With Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-week Trial of Risperidone and Olanzapine. Annals of Clinical Psychiatry. 2008;20:71-8. PMID:18568578
57. Kelly DL, Weiner E, Conley RR, McMahon RP, Buchanan RW.  Lack of Beneficial Galantamine Effect for Smoking Behavior: A Double-Blind Randomized Trial in People with Schizophrenia. Schizophrenia Research. 2008;103;161-8. PMID:18550339
58. Shim JC, Liu Y-S, Kelly DL. Aripiprazole Treatment Causes Extrapyramidal Side Effects but Not Prolactin Elevations: A Disconnect of the Striatal D₂ Occupancy Story. J Clin Psychopharmacology. 2008;28(3):353-354. PMID:18480699
59. Boggs DL, Kelly DL, Nelson MW, Yu Y, Feldman S, McMahon RP, Conley RR. Quetipine at High doses for Treatment Refractory Schizophrenia.  Schizophrenia Research. 2008;101:347-8. PMID:18281197
60. McMahon RP, Kelly DL, Boggs DL, Li L, Hu Q, Davis JM, Carpenter WT. Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research. Schizophrenia Bull. 2008;34:298-301. PMID:18184634
61. Boggs DL, Kelly DL, Love RC, McMahon RP, Conley RR. Comparison of Clozapine Response for Inpatients in the Research Setting versus Routine Clinical Practice. Psychiatric Quarterly. 2008;79(2):111-119. PMID:18214677
62. Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL,Goodwin RS, Gorelick DA, Huestis MA. Δ⁹-Tetrahydrocannabinol (THC), 11-Hydroxy-THC & 11-nor-9-Carboxy-THC Plasma Pharmacokinetics During and Following Continuous High Dose Oral THC. Clinical Chemistry. 2009;55:2180-9. PMID: 19833841
63. Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Nelson M, Dickinson D, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. A randomized double blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clinical Psychiatry. 2009;70(4):518-25. PMID: 19358788.
64. Kelly DL, Linthicum J, Wehring HJ, Feldman S, McMahon RP, Lover RC, Wagner T, Shim J-C, Fowler DR. Cardiac-Related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophrenia Research. 2009;107:134-8. PMID:19028422
65. Conley RR, Boggs DL, Kelly DL, McMahon RP, Feldman S, Ball P, Buchanan RW. The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia. Clinical Neuropharmacology. 2009;32;69-74. PMID:18978489
66. Kelly DL, Weiner E, Ball MP, McMahon RP, Carpenter WT, Buchanan RW. Remission in Schizophrenia: The Relationship to Baseline Symptoms and Changes in Symptom Domains During a One-Year Study. J of Psychopharmacology. 2009:23;436-41. PMID:18583442
67. Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71:304-11. PMID: 20079332
68. Kelly DL, Feldman S, Boggs DL, Gale E, Richardson CM, Conley RR. Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Comprehensive Psychiatry. 2010;51;298-302. PMID 20399340
69. Wehring HJ, Liu F, McMahon RP, Spieker EA, Warren KR, Boggs DL, Love RC, Dickinson D, Shim JC, Fowler D, Kelly DL. The relationship of brain weight to body mass index (BMI) upon autopsy in young people with severe mental illness. Schizophrenia Research. 2010;123:86-7.  PMID:20800997
70. Weiner E, Conley RR, Ball MP, Feldman S, Gold JM, Kelly DL, Wonodi I, McMahon RP, Buchanan RW. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine Neuropsychopharmacology. 2010;35;2274-83. PMID: 20664583
71. Milman G, Barnes AL, Schwope DM, Schwilke EW, Darwin WD, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA.  Disposition of Cannabinoids in Oral Fluid Following Controlled Around-the-Clock Oral THC Administration. Clinical Chemistry. 2010;56:1261-9. PMID: 20530732
72. Levin KH, Copersino ML, Heishman SJ, Liu F, Kelly DL, Boggs DL, Gorelick DA. Cannabis Withdrawal Symptoms in Non-Treatment-Seeking Adult Cannabis Smokers.  Drug and Alcohol Dependence. 2010;111:120-7. PMID: 20510550
73. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Fischer BA, Himelhoch S, Boggs DL, Fang B, Peterson E, Aquino PR, Keller W. The 2009 SchizophreniaPORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophr Bull. 2010;36;71-93. PMID: 19955390
74. Wehring HJ, Thedford S, Koola M, Kelly DL. Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia Disease. 2011;3:107-23. PMID: 23293546
75. Jung DU, Kelly DL, Oh MK, Kong BG, Kang JW, Lee SJ, Shim JC: Bone Mineral Density and Osteoporosis Risk in Older Patients With Schizophrenia. J Clinical Psychopharmacology. 2011;31:406-10. PMID: 21694624
76. Kelly DL, Myers CS, Abrams MT, Feldman S, Park J, McMahon RP, Shim JC. The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders. Osteoporosis Int. 2011;22(4):1133-43. PMID: 20533029
77. Milman G, Barnes AJ, SchwopeDM, Schwilke EW, Goodwin RS, KellyDL, GorelickDA,  Huestis MA: Cannabinoids and metabolites in expectorated oral fluid after eight days of controlled around-the-clock oral THC administration. Analytical and Bioanalytical Chemistry, 2011;401:599-607. PMID: 21637933
78. Cascella NG, Kryszak D, Bhatti B, Gregory P, Kelly DL, Mc Evoy JP, Fasano A, Eaton WW. Prevalence of celiac disease and gluten sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness Study Population. Schizophr Bull. 2011;37:94-100, PMID:19494248.
79. Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW: Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011. Apr;5(1):17-25. PMID: 21459735
80. Lo S, Raley HG, Heishman SJ, Wright K, Wehring HJ, Moolchan ET, Feldman S, Liu F, McMahon RP, Richardson CM, Kelly DL. Cigarette Craving and Dependency in People with Schizophrenia Compared to Normal Controls. Schizophrenia Research. 2011;127:241-5. PMID: 20637571.
81. Kelly DL, McMahon RP, Wehring H, Liu F, Mackowick K, Boggs DL, Warren KR, Feldman S, Shim JC, Love RC, Dixon L. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bulletin. 2011;37:832-8, PMID: 20019128
82. Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, Kelly DL. Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.  Schizophr Res. 2011 Jun;129(1):94-5. PMID: 21376537
83. Kelly DL, Gorelick DA, McMahon RP, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Richardson CM, Conley RR, Gold JM, Wehring HJ, Kearns AM, Huestis MA, Buchanan RW. Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms In Overweight People with Schizophrenia: A Randomized, Double-Blind Pilot Study, J Clinical Psychopharmacology, 2011;31:86-91 PMID: 21192149
84. Warren KR, Ball MP, Feldman S, Liu F, McMahon RP, Kelly DL. Exercise program adherence using a 5-kilometer event and an achievable goal in people with schizophrenia.             Biol Res Nurs 2011;13:383-90. PMID: 21196420
85. Kelly DL, Vyas G, Richardson CM, Koola MM, McMahon RP, Buchanan RW, Wehring HJ. Adjunct Minocycline to Clozapine in Treatment Resistant Schizophrenia. Schizophrenia Research. 2011;13:257-8. PMID: 21872445
86. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA. Antagonist-elicited cannabis withdrawal in humans. J Clin Psychopharmacol 2011;31:603-12. PMID: 251869692
87. Kelly DL, Thedford S, Vyas G. A new blood-based diagnostic aid for schizophrenia. Psychiatr Serv 2011;62:1107. PMID: 21885596
88. Milman G, Schwope DM, Schwilke EW, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Oral fluid and plasma cannabinoid ratios afer around-the-clock controlled oral [delta]9-tetrahydrocannabinol administration. Clin Chem 2011;57:1597-606. PMID: 21875944
89. Goodwin RS, Baumann MH, Gorelick DA, Schwilke E, Schwope DM, Darwin WD, Kelly DL, Schroeder JR, Ortemann-Renon C, Bonnet D, Huestis MA. CB1-Cannabinoid receptor          antagonist effects on Cortisol in cannabis-dependent men. Am J Drug Alcohol Abuse 2012;38:114-9 PMID: 2179781
90. Koola M, Fawcett JA, Kelly DL. Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement based care. Journal of Nervous and Mental Disease, 2011;199:989-990.  PMID: 22134460
91. Wehring HJ, Thedford S. Koola M, Kelly DL. Patient and health care provider perspectives on long acting antipsychotics in schizophrenia and the introduction of olanzapine long acting injection. J Cent Nerv Syst Dis 2011;3:107-123. PMID: 23293546
92. Jackson J, Eaton W, Cascella N, Fasano A, Kelly DL.  Neurologic and Psychiatric Manifestations of Celiac Disease and Gluten Sensitivity.  Psychiatric Quarterly.  2012;83:91-102.  PMID: 21877216.
93. Boggs DL, Kelly DL, RP McMahon, Gold JM, Gorelick DA, Linthicum J, Conley RR, Liu F, Waltz J, Huestis MA, Buchanan RW. Rimonabant for neurocognition in schizophrenia: a 16 week double blind randomized placebo controlled trial. Schizophr Res, 2012;134:207-10. PMID: 22137462
94. Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL.  Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia:  A Randomized Double-Blind Placebo-Controlled Trial.  Neuropsychopharmacology 2012;37:660-668  PMID:  22048460
95. Koola MM, Brown WV, Qualls C, Cuthbert B, Hollis JP, Kelly DL, Le NA, Raines J, Duncan EJ. Reduced arterial compliance in patients with psychiatric diagnoses. Schizophr Res 2012; 137:251-3. PMID: 22377105
96. Gorelick D, Levin KH, Copersino ML, Heishman SJ, Liu F, Boggs DL, Kelly DL. Diagnostic criteria for cannabis withdrawal syndrome. Drug and Alcohol Dependence, 2012:123:141-7. PMID: 22153944
97. Karschner EL, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA. Predictive model accuracy in estimating last D(9)-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend 2012;125:313-9. PMID: 22464363.
98. Abrams M, Myers C, McMahon RP, Kelly DL. Cervical cancer screening and associated acute care rates for Medicaid enrollees with mental and substance use disorders. Psychiatric Services, 2012;63:815-22. PMID: 22666450.
99. Kelly DL, Wehring HJ, Vyas G. The current use of clozapine in the US. Shanghai Arch of Psychiatry, 2012;24:110-113.
100. Mackowick KM, Heishman SJ, Wehring HJ, Liu F, McMahon RP, Kelly DL. Illicit drug use in heavy smokers with and without schizophrenia. Schizophr Res, 2012;139:194-200.  PMID: 22591779.
101. Wehring HJ, Liu F, McMahon RP, Mackowick KM, Love RC, Dixon L, Kelly DL. Clinical characteristics of heavy and non-heavy smokers with schizophrenia. Schizophr Res 2012:138:285-9. PMID: 22578720
102. Koola M, Wehring HJ, Kelly DL. The potential role of long acting injectable antipsychotics in dually diagnosed people with schizophrenia. Journal of Dual Diagnosis, 2012;8:50-61. PMID: 22754405
103. Abrams MT, Myers CS, Feldman SM, Boddie-Willis C, Park K, McMahon RP, Kelly DL. Cervical cancer screening and acute care visits among Medicaid enrollees with mental and substance use disorders. Psychiatr Serv 2012;63:815-22. PMID: 22660581
104. Koola MM, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Warren KR, Feldman S, Shim JC, Love RC, Kelly DL. Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychatriat Res 2012;46:987-93. PMID: 22595870.
105. Kelly DL, Raley H, Lo S, Wright K, Moolchan E, Feldman S, Liu F, McMahon RP, Richardson CM, Jaszyna-Gasior M, Wehring HJ, Boggs D, Heishman S. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophrenia Bull. 2012;38:543-51.  PMID: 21041835
106. Jackson J, Eaton W, Cascella N, Fasano A, Warfel D, Feldman D, Richardson C, Vyas G, Linthicum J, Santora D, Warren KR, Carpenter WT, Jr, Kelly DL. A gluten free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res 2012;140:262-3. PMID: 22771303
107. Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 2013;27:337-42. PMID: 23151612.
108. Boggs DL, Kelly DL, Liu F, Linthicum J, Turner H, Schroeder JR, McMahon RP, Gorelick DA. Cannabis withdrawal in chronic cannabis users with schizophrenia. J Psychiatr Res 2013;47:340-5. PMID: 23146560
109. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA. Tolerance to Effects of High-Dose Oral [Delta}9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers. J Anal Toxicol 2013;37:11-6. PMID:  2307421
110. Cascella NG, Santora D, Gregory P, Kelly DL, Fasano A, Eaton WW. Increased prevalence of transglutaminase 6 antibodies in sera from schizophrenia patients. Schizophr Bull 2013;39:867-71. PMID: 22516148
111. Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind pilot study. J Clin Psychopharmacol 2013;33:118-20.  PMID:  23277241.
112. Okusaga O, Yolken RH, Langenberg P, Sleemi A, Kelly DL, Vaswani D, Giegling I, Hartmann AM, Konte B, Friedl M, Mohyuddin F, Groer MW, Rujescu D, Postolache TT. Elevated gliadin antibody levels in individuals with schizophrenia. World J Biol Psychiatry 2013;14:509-15. PMID: 23282016.
113. Lee MR, Wehring HJ, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL. Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study. Schizophr Res. 2013;145:110-5. PMID: 23415472
114. Koola MM, Qualls C, Kelly DL, Skelton K, Bradley B, Amar R, Duncan EJ. Prevalence of  childhood physical and sexual abuse in veterans with psychiatric diagnoses. J Nerv Ment Dis 2013;201:348-52. PMID: 23538982
115. Koola MM, Boggs DL, Kelly DL, Linthicum JA, Turner HE, McMahon RP, Gorelick DA.  Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia. Psychiatry Res 2013;30:273-8. PMID: 23969281
116. Kelly DL, Wehring HJ, Earl AK, Sullivan K, Dickerson FB, Feldman S, McMahon RP, Buchanan RW, Warfel D, Keller WR, Fischer BA, Shim JC.   Treating symptomatic hyperprolactinemia in    women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated proactin).  BMC Psychiatry 2013;13:214 PMID: 23968123.
117. Gorelick DA, Goodwin RS, Schwilike E, Schoreder JR, Schwope DM, Kelly DL, Ortemann-    Renon C, Bonnet D, Huestis MA. Around the clock oral THC effects on sleep in male chronic  daily cannabis smokers. Am J Addict 2013;22:510-4.  PMID:  23952899.
118. Wehring HJ,  Perez G, Dixon L, Kelly DL. Women and Drug and Alcohol Use Disorders: Compounding the Picture with Severe Mental Illness. Current Women’s Health Reviews 2013; 9(3):183-188.
119. Ben-Yoav H, Winkler TE, Kim E, Chocron SE, Kelly DL, Payne GF, Ghodssi R.  Redox cycling- based amplifying electrochemical sensor for in situ clozapine antipsychotic treatment monitoring. Electrochimica Actra 2014;130:497-503.
120. Koola MM, Gorelick DA, McMahon RP, Liu F,  Huestis M, Linthicum J, Feldman S, Warren KR, Wehring HJ, Kelly DL. Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder, Schizophr Res 2014; 152:315-316.  PMID:  24333005.
121. Warren KM, Postolache TT, Groer ME, Pinjari O, Kelly DL, Reynolds MA. Role of chronic stress and depression in periodontal diseases. Periodontol 2000 2014 Feb; 64(1):127-138. PMID:  24320960.
122. Goldstein JI, Fredrik Jarskog L, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, Dettling M, Gazit E, Goff DC, Holden AL, Kelly DL, Malhotra AK, Nielsen J, Pirmohamed M, Rujescu D, Werge T, Levy DL, Josiassen RC, Kennedy JL, Lieberman JA, Daly MJ, Sullivan PF. Clozapine –induced agranulocytosis is associated with rare HLA-DQB1 and HLA alleles. Nat Commun 2014;5:4757. PMID: 25187353.
123. Lee MR, Glassman M, King-Casas B, Kelly DL, Stein EA, Schroeder J, Salmeron BJ. Complexity of oxytocin’s effects in a chronic cocaine dependent population. Eur Neuropsychopharmacol 2014;9:1483-91. PMID: 25044050.
124. Yu M, Hassan HE, Ibrahim A, Bauer KS, Kelly DL, Wang JB. Simultaneous determination of l-tetrahydroplamatine and cocaine in human plasma by simple UPLC-FLD method: Application to clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci 2014;15:965-44. PMID: 24996068.
125. Jackson J, Eaton W, Cascella N, Fasano A, Santora D, Sullivan K, Feldman S, Raley H, McMahon RP, Carpenter WT Jr, Demyanovich H, Kelly DL. Gluten Sensitivity and relationship to psychiatric symptoms in people with schizophrenia. Schizophr Res 2014;159:539-42. PMID: 25311778.
126. Winkler T, Ben-Yoav H, Chocron S, Kim E, Kelly DL, Payne G, Ghodssi R. Electrochemical Study of the Catechol-modified Chitosan System for Clozapine Treatment Monitoring. Langmuir 2014;30:14686-93.
127. Fischer BA, McMahon RP, Kelly DL, Wehring HJ, Meyer WA, Feldman S, Carpenter WT, Gorelick DA. Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophr Res 2015;161:471-7. PMID: 25467541.
128. Evins AE, Hong LE, Kelly DL. T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis. Eur Arch Psychiatry Clin Neurosci 2015;265:269-70. PMID: 25377170.
129. Ben-Yoav H, Chocron SE, Winkler TE, Kim E, Kelly DL, Payne GF, Ghodssi R.  An electrochemical micro-system for clozapine antipsychotic treatment monitoring.  2015 May; (163):260-270.
130. Buchanan RW, Weiner E, Kelly DL, Gold JM, Keller WR, Waltz JA, McMahon RP, Gorelick DA. Rasagiline in the treatment of persistant negative symptoms of schizophrenia. Schizophr Bull 2015;41:900-8. PMID: 25368372.
131. Chocron SE, Weisberger BM, Ben-Yoave H, Winkler TE, Kim E, Kelly DL, Payne GF, Ghodssi R. Multi-deimensional mapping method using an arrayed sensing system for cross reactivity screening. PLoS One  2015;10:e0116310.  PMID: 25789880.
132. Eaton WW, Chen LY, Dohan FC Jr. Kelly DL, Cascella N. Improvement in psychotic symptoms after a gluten-free diet in a boy with complex autoimmune illness. Am J Psychiatry 2015;172:219-21. PMID: 25727533.
133. Kim E, Chocron SE, Ben-Yoav H, Winkler TE, Liu Y, Glassman M, Wolfram C, Kelly DL, Ghodssi R, Payne GF.  Programmable “semismart” sensor:  relevance to monitoring antipsychotics.  Adv Funct Mater, 2015;25:2156-2165.
134. Kelly, DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman, SM, Russ JC, Keefe RS, Osing J, Hubzin L, August A, Walker TM, Buchanan RW.  Adjunctive Minocycline in clozapine treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol. 2015 Aug;35(4):374-81. doi: 10.1097/JCP.0000000000000345. PMID: 26082974
135. Miller J, Wehring H, McMahon R, DiPaula B, Love R, Davies K, Morris AA, Raley H, Feldman S, Warfel D, Kelly DL.  Urine testing for antipsychotics: a pilot trial for a method to determine detection levels. Hum Psychopharmacol. 2015 Sep;30(5):350-5. doi: 10.1002/hup.2482. Epub 2015 May 25. PMID: 26010339.
136. Eaton WW, Chen LY, Dohan FC, Jr, Kelly DL, Cascella N. Response to Ell’Osso and Elli. Am J Psychiatry. 2015 Jul;172(7):686. PMID: 26130205
137. Kelly DL*, Ben-Yoav H*, Payne GF, Winkler TE, Chocron SE, Kim E, Stock V, Yvas G, Love RC, Wehring HJ, Sullivan KM, Feldman SF, Liu F, McMahon RP, Ghodssi R.  Blood draw barriers for treatment with clozapine and development of point-of-care monitoring device. Clinical Schizophrenia & Related Disorders, 2015 Jul 28. [Epub ahead of print] PMID: 26218235.
138. Koola MM, Sullivan KM, Earl AK, Feldman SM, Richardson CM, Vyas GR, Wehring HJ, Kelly DL.  Undiagnosed Lyme disease in adults with schizophrenia. Schizophr Res. 2015 Oct;168(1-2):579-80. PMID: 26255567.
139. Patchan KM, Richardson C, Vyas G, Kelly DL.  The risk of suicide after clozapine discontinuation: cause for concern.  Ann Clin Psychiatry, 2015 Nov; 27(4):253-256.  PMID: 26554366.
140. Kelly DL, Rowland LM, Patchan KM, Sullivan K, Earl A, Raley H, Liu F, Feldman S, McMahon RP.  Schizophrenia clinical symptom differences in women vs men with and without a history of childhood physical abuse.  Child Adolesc Psychiatry Ment Health.  2016;10(5):doi: 10.1186/s13034-016-0092-9.  PMID:  26941836
141. Lee MR, Wehring HJ, McMahon RP, Liu F, Linthicum J, Verbalis JG, Buchanan RW, Strauss GP, Rubin LH, Kelly DL.  Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia.  Schizophr Res 2016;172(1-3):165-8.  PMID:  26879587
142. Okusaga, O, Fuchs, D, Reeves G, Giegling I, Hartmann AM, Konte B, Friedl M, Groer M, Stearns-Yoder KA, Pandey JP, Kelly DL, Hoisington AJ, Lowry CA, Eaton WW, Brenner LA, Rujescu D, Postolache TT.  Kynurenine and trypophan levels in patients with schizophrenia and elevated anti-gliadin immunoglobulin G antibodies.  Psychosomatic Medicine.  2016;78:931-939. PMID: 27359171
143. Koola MM, Kelly DL, McMahon RP, Boggs DL, Liu F, Gorelick DA.  Psychoactive substance use by adults with schizophrenia before and during cannabis withdrawal.  Prim Care Companion CNS Disord. 2016 Sep 1;18(5).  PMID:  27835727
144. Legge SE, Hamshere ML, Ripke S, Pardinas AF, Goldstein JI, Rees E, Riahcards AL, Leonenko G, Jarskog LF, Clozapine-Induced Agranulocytosis Consortium. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated Neutropenia. Mol Psychiatry 2016 epub ahead of print  PMID: 27400856
145. Norman SM, Sullivan KM, Liu F, DiPaula BA, Jose PA, Kitchen CA, Feldman SM, Kelly DL. Blood pressure and heart rate changes during clozapine treatment. Psychiatr Q 2016, epub ahead of print. PMID: 27678498
146. Richardson CM*, Davis EA,* Vyas GR, DiPaula BA, McMahon RP, Kelly DL. Evaluation of the safety of clozapine use in patients with benign neutropenia.  J Clin Psych 2016;77(11):e1454-e1459.  PMID: 27736047.
147. Koola MM, Kelly DL, McMahon RP, Boggs D, Liu F, Gorelick DA. Substance use by adults with schizophrenia before and during cannabis withdrawal.  Prim Care Companion CNS Disord. 2016;18(5).  PMID:  27835727
148. Kowalczyk WJ, Wehring HJ, Burton G, Raley H, Feldman S, Heishman SJ, Kelly DL.  Predictors of the perception of cigarette health risks in smokers with and without schizophrenia.   J of Dual Diagnosis.  2017 Jan-Mar;13(1)29-35.  PMID: 27858591
149. Kim E, Liu Y, Ben-Yoav H, Winkler TE, Yan K, Shi X, Shen J, Kelly DL, Ghodssi R, Bentley WE, Payne GF.  Fusing sensor paradigms to acquire chemical information: an integrative role for smart biopolymeric hydrogels.  Adv Healhcare Materials 2016;5:2595-2616. PMID: 27616350
150. Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, Kelly DL, Cascella N, Fasano A. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism 2016:7:49. PMID: 27957319
151. Shovestul B, Glassman M, Rowland LM, McMahon RP, Liu F, Kelly DL.  Pilot study examining the relationship of childhood trauma, perceived stress, and medication use to serum kynurenic acid and kynurenine levels in schizophrenia.  Schiz Research.  2017;185:200-1. PMID: 28082139
152. Hassan HE*, Kelly DL*, Honick M, Shukla S, Ibrahim A, Gorelick DA, Glassman M, McMahon RP, Wehring HJ, Kearns AM, Feldman S, Yu M, Bauer K, Wang JB.  Pharmacokinetics and safety assessment of l-tetrahydropalmatine in cocaine users: a randomized, double-blind, placebo controlled study.  Clinical Pharmacology & Therapeutics. J Clin Pharmacol. 2017 Feb;57(2):  151-160.  PMID:  27363313.
153. Xiang YQ, Zheng W, Wang SB, Yang XH, Cai DB, Ng CH, Ungvari GS, Kelly DL, Xu WY, Xiang YT.  Adjunctive Minocycline for schizophrenia: a meta-analysis of randomized controlled trials.  European Neuropsychopharmacology.  2017;27:8-18. PMID: 27919523
154. Kim E, Winkler TE, Kitchen C, Kang M, Banis GE, Bentley WE, Kelly DL, Ghodssi R, Payne GF.  Redox probing for chemical information of oxidative stress.  Anal Chem 2017;89:1583-92. PMID: 28035805
155. Wehring HJ, Heishman SJ, McMahon RP, Liu F, Feldman S, Raley H, Weiner E, Kelly DL.  Antipsychotic treatment and tobacco craving in people with schizophrenia.  Journal of Dual Diagnosis.  2017;13:36-42 PMID: 28166471
156. Cohen AS, Mitchell KR, Strauss GP, Blanchard JJ, Buchanan RW, Kelly DL, Gold J, McMahon RP, Adams HA, Carpenter WT. The effects of oxytocin and galantamine on obejectivity-defined vocal and facial expression: data from the CIDAR study. Schizophr Res  2017;188:141-143. PMID: 28130004
157. Kang M, Kim E, Winkler TE, Banis G, Liu Y, Kitchen CA, Kelly DL, Ghodssi R, Payne GF.  Reliable clinical serum analysis with reusable electrochemical sersor:  Toward point-of-care measurement of the antipsychotic medication clozapine.  Biosens Bioelectron.  2017 Apr 12;95:55-59.  PMID: 28412661
158. Winkler TE, Lederer SL, Kim E, Ben-Yoav H, Kelly DL, Payne GF, Ghosssi R.  Molecular processes in an electrochemical clozapine sensor. Biointerphases. June 2017;12(2):02B401.
159. Winkler TE, Dietrich R, Kim E, Ben-Yoav H, Kelly DL, Payne GF, Ghodssi R.The interplay of electrode- and bio-materials in a redox-cycling-based clozapine sensor.  Electrochemistry Communications.  Electrochemistry Communications.  2017 June (79):33-36. PMID: 28460529
160. Buchanan RW, Kelly DL, Weiner E, Gold JM, Strauss GP, Koola MM, McMahon RP, Carpenter WT.  A randomized clinical trial of oxytocin or galantamine for the treatment of negative symptoms and cognitive impairments in people with schizophrenia.  J Clin Psychopharmacology 2017;37:394-400  PMID: 28590362
161. Patchan K, Vyas G, Hackman AL, Mackowick M, Richardson CM, Love RC, Wonodi I, Sayer MA, Glassman M, Feldman S, Kelly DL.  Clozapien in reducing aggression and violence in forensic populations. Psych Quarterly 2017. Epub ahead of print.  PMID: 28643049
162. Wehring HJ, Elsobky T, McEvoy JP, Vyas G, Richardson CM, McMahon RP, DiPaula BA, Liu F, Sullivan K, Buchanan RW, Feldman S, McMahon RP, Kelly DL. Adjunctive minocycline in clozapine-treated patients with schizophrenia: analyzing the effects of minocycline on clozapine plasma levels. Psych Quarterly 2017; epub ahead of print. PMID: 28466366
163. Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, Feldman S, Kelly DL.   Gliadin-related antibodies in schizophrenia. Schizophrenia Research, 2017, epub ahead of print  PMID: 28886891
164. Banis GE, Winkler TE, Barton P, Chocron SE, Kim E, Kelly DL, Payne GF, Ben-Yoav H, Ghodssi R. The binding effects of proteins on medications and its impact on electrochemical sensing: antipsychotic clozapine as a case study.  Pharmaceuticals. 2017;10: pii: E69. doi: 10.3390/ph10030069. PMID: 28763030
165. Kang M, Kim E, Winkler TE, Banis G, Liu F, Kitchen C, Kelly DL, Ghodssi R, Payne GF.  Electrodeposited graphene-chitosan composite film for therapeutic drug monitoring.  Biosens Bioelectron.  2017;95:55-59  PMID   28412662.
166. Rowland LM, Demyanovich HA, Witjenberg SA, Eaton WW, Rodriguez K, Gaston F, Cihakova D, Talor MV, Liu F, McMahon RP, Hong LE, Kelly DL.  Antigliadin Antibodies (AGA IgG) Are Related to Neurochemistry in Schizophrenia. Frontiers in Psychiatry 2017:8:104  PMID 28674804
167. Temocin Z, Kim E, Li J, Panzella L, Alfierei ML, Japolitano A, Kelly DL, Bently WE, Payne GF. The analgesic acetaminophen and antipsychotic clozapine can each redox-cycle with melanin. ACS Chem Neuroscien 2017;8(12);2766-2777. PMID 28945963
168. Kelly DL, Freudenreich O, Sayer MA, Love RC. Addressing barriers to clozapine underutilization: a national effort. Psychiatr Serv 2018;69:224-227. PMID  29032704
169. Rubin LH, Wehring HJ, Demyanovich H, Carter S, Pournajafi-Nazarloo H, Feldmand SM, Earl AK, August S, Gold JM, Kelly DL. Peripheral oxytocin and vasopressin are associated with clinical symptom severity and cognitive functioning in midlife women and chronic schizophrenia. Schizophr re 2018;195:409-411. PMID   28965776
170.  Liu Y, Li J, Tschirhart T, Terrell JL, Kim E, Tsao CY, Kelly DL, Bentley WE, Payne GF. Connecting biology to electronics: molecular communication via redoz modality. Adv Healthc Mater 2017, epub ahead of print.   PMID 29045017
171. Kelly DL, Demyanovich HK, Eaton W, Cascella N, Jackson J, Fasano A, Carpenter WT. Antigliadin antibodies (AGA IgG) related to peripheral inflammation in schizophrenia. Brain Behav Immun 2018;69:57-59. PMID  29074356
172. Kang M, Kim E, Chen S, Bentley WE, Kelly DL, Payne GF. Signal processing approach to probe chemical space for discriminating redox signatures. Biosens Bioelectron 2018;112:127-135. PMID 29702384
173. Wehring HJ, Buchanan RW, Feldman S, Carpenter WT, McMahon RP, Weiner E, Gold JM, Adams HA, Strauss GP, Rubin LH, Kelly DL. Oxytocin and sexual function in males and females with schizophrenia. Schizophr Res 2018 March 15 pii: S0920-9964(18)30165-8. doi: Epub ahead of print PMID: 29551232
174. Warren KR, Wehring HJ, Liu F, McMahon RP, Chen S, Chester C, Kelly DL. Effects of intranasal oxytocin on satiety signaling in people with schizophrenia. Physiol Behav. 2018;189:86-91 PMID: 29524451
175. Winkler TE, Stevenson FO, Kim E, Kang M, Payne GF, Kelly DL, Ghodssi R. Treatment monitoring in schizophrenia. The role of microsystems integration towards point-of-care clozapine. IEEE Sens Lett. 2018;1: pii: 5500304. Dec 13. PMID: 29308452
176. Kelly DL*, Ben-Yoav H*, Payne GF, Winkler TE, Chocron SE, Kim E, Stock V, Yvas G, Love RC, Wehring HJ, Sullivan KM, Feldman SF, Liu F, McMahon RP, Ghodssi R.  Blood draw barriers for treatment with clozapine and development of point-of-care monitoring device. Clinical Schizophrenia & Related Disorders, 2018;12:23-30 PMID: 26218235
177. Kelly DL, Wehring HJ. Minocycline as an evidence-based adjunct treatment in schizophrenia. Psychiatric Annals. CME article. 2018;48(5): 224-231
178. Wilson K, Kilday C, Rubin L, Wehring H, Demyanovich H, Feldman S, Kelly DL. Relationship of Interferon-γ to Cognitive Function in Midlife and Post-Menopausal Women with Schizophrenia. Psychiatr Q. 2018 Jul 26. PMID: 30051373
179. Kelly DL, Powell MM, Wehring HJ, Sayer MA, Kearns AM, Hackman AL, Buchanan RW, Nichols RB, Adams HA, Richardson CM, Vyas G, McMahon RP, Earl AK, Sullivan KM, Liu F, Luttrell SE, Dickerson FB, Feldman SM, Narang S, Koola MM, Buckley PF, RachBeisel JA, McEvoy JP. Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial. J Clin Psychopharmacol. 2018 Aug;38(4):317-326. PMID: 29912799
180. Kelly DL, Li X, Kilday C, Feldman S, Clark S, Liu F, Buchanan RW, Tonelli LH. Increased circulating regulatory T cells in medicated people with schizophrenia. Psychiatry Res. 2018 Sep 5;269:517-523. doi: 10.1016/j.psychres.2018.09.006. [Epub ahead of print] PMID: 30195746
181. Glassman M, Wehring HJ, Pocivavek A, Sullivan KM, Rowland LM, McMahon R, Chiappelli J, Liu F, Kelly DL. Peripheral Cortisol and Inflammatory Response to a Psychosocial Stressor in People with Schizophrenia. Journal of Neuropsychiatry 2018 May 23 DOI: 10.21767/2471-8548.10008
182. Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, Feldman S, Kelly DL. Gut permeability and mimicry of the Glutamate Ionotropic Receptor NMDA type Subunit Associated with protein 1 (GRINA) as potential mechanisms related to a subgroup of people with schizophrenia with elevated antigliadin antibodies (AGA IgG). Schizophr Res 2019 Jun;208:414-419. doi: 10.1016/j.schres.2019.01.007. Epub 2019 Jan 24 PMID: 30685393
183. Stolz PA, Wehring HJ, Liu F, Love RC, Ellis M, DiPaula BA, Kelly DL. Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia. Psychiatr Q.2019 Jan 10. doi: 10.1007/s11126-018-9621-4. [Epub ahead of print] PMID: 30632082
184. Strauss GP, Granholm E, Holden JL, Ruiz I, Gold JM, Kelly DL, Buchanan RW. The effects of combined oxytocin and cognitive behavioral social skills training on social cognition in schizophrenia. Psychol Med. 2019 Jul;49(10):1731-1739. doi: 10.1017/S0033291718002465. Epub 2018 Sep 5. PMID: 30180918
185. Kelly DL, Demyanovich HK, Rodriguez KM, Ciháková D, Talor MV, McMahon RP, Richardson CM, Vyas G, Adams HA, August SM, Fasano A, Cascella NG, Feldman SM, Liu F, Sayer MA, Powell MM, Wehring HJ, Buchanan RW, Gold JM, Carpenter WT, Eaton WW. Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study. J Psychiatry Neurosci.2019 Jul 1;44(4):269-276. PMID: 30938127
186. Cihakova D, Eaton WW, Talor MV, Harkus UH, Demyanovich H, Rodriguez K, Feldman S, Kelly DL. Gut permeability and mimicry of the Glutamate Ionotropic Receptor NMDA type Subunit Associated with protein 1 (GRINA) as potential mechanisms related to a subgroup of people with schizophrenia with elevated antigliadin antibodies (AGA IgG). Schizophr Res.2019 Jan 23. pii: S0920-9964(19)30007-6. doi: 10.1016/j.schres.2019.01.007. [Epub ahead of print] PMID: 30685393
187. Kelly DL, Love RC. Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management. Ment Health Clin. 2019 Mar 1;9(2):64-69. doi: 10.9740/mhc.2019.03.064. eCollection 2019 Mar. PMID: 30842912 PMCID: PMC6398355
188. Stolz PA, Wehring HJ, Liu F, Love RC, Ellis M, DiPaula BA, Kelly DL. Effects of Cigarette Smoking and Clozapine Treatment on 20-Year All-Cause & Cardiovascular Mortality in Schizophrenia. Psychiatr Q. 2019 Jun;90(2):351-359. doi: 10.1007/s11126-018-9621-4. PMID: 30632082
189. Davis EAK, Kelly DL. Clozapine-associated renal failure: A case report and literature review. Ment Health Clin.2019 May 10;9(3):124-127. doi: 10.9740/mhc.2019.05.124. eCollection 2019 May. PMID: 31123659
190. Lee MR, Wehring HJ, McMahon RP, Liu F, Linthicum J, Buchanan RW, Strauss GP, Rubin LH, Kelly DL. The Effect of Intranasal Oxytocin on Measures of Social Cognition in Schizophrenia: A Negative Report. J Psychiatr Brain Sci.2019;4(1). pii: e190001. doi: 10.20900/jpbs.20190001. Epub 2019 Jan 9. PMID: 31037274
191. Barber GS, Sturgeon C, Fasano A, Cascella N, Eaton WW, McMahon RP, Kelly DL. Elevated zonulin, a measure of tight-junction permeability, may be implicated in schizophrenia. Schizophr Res. 2019 Sep;211:111-112. doi: 10.1016/j.schres.2019.07.006. Epub 2019 Jul 12. No abstract available. PMID: 31307857
192. Kim E, Keskey Z, Kang M, Kitchen C, Bentley WE, Chen S, Kelly DL, Payne GF. Validation of oxidative stress assay for schizophrenia. Schizophr Res. 2019 Oct;212:126-133. doi: 10.1016/j.schres.2019.07.057. Epub 2019 Aug 6. PMID: 31399268
193. Kalaria SN, Kelly DL. Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes. Neuropsychiatr Dis Treat. 2019 Aug 20;15:2365-2370. doi: 10.2147/NDT.S216803. eCollection 2019. PMID: 31692521
194. Shukla RP, Cazelles R, Kelly DL, Ben-Yoav H. A reduced-graphene oxide-modified microelectrode for a repeatable detection of antipsychotic clozapine using microliters-volumes of whole blood. Talanta. 2020 Mar 1; 209:120560. doi: 10.1016/j.talanta.2019.120560. Epub 2019 Nov 14. PMID: 31892051
195. Kim E, Li J, Kang M, Kelly DL, Chen S, Napolitano A, Panzella L, Shi X, Yan K, Wu S, Shen J, Bentley WE, Payne GF. Redox Is a Global Biodevice Information Processing Modality. Proc IEEE Inst Electr Electron Eng. 2019 Jul; 107(7):1402-1424. doi: 10.1109/JPROC.2019.2908582. Epub 2019 Apr 29. PMID: 32095023
196. Kelly DL, Gorelick DA, Wehring HJ, Vyas G, Buchanan RW. Treatments for the Prevention and Management of Suicide. Ann Intern Med. 2020 Jan 21;172(2):167-168. doi: 10.7326/L19-0706. No abstract available. PMID: 31958830
197. Gannon JM, Kelly DL, Besch A, Thakur T, Khurana N, Shurin MR, Shurin GV, Brar JS, Cihakova D, Talor MV, Chengappa KNR. Racial Differences in S100b Levels in Persons with Schizophrenia. Psychiatr Q. 2020 Mar;91(1):137-145. doi: 10.1007/s11126-019-09687-4. PMID: 31786729
198. Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, Kane JM, Kelly DL, Laitman R, Lee J, MacCabe JH, Myles N, Nielsen J, Schulte PF, Taylor D, Verdoux H, Wheeler A, Freudenreich O. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatry Neurosci. 2020 Apr 3;45(4):200061. doi: 10.1503/jpn.200061. [Epub ahead of print] PMID: 32242646.
199. Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Gründer G, American Society of Clinical Psychopharmacology; The Therapeutic Drug Monitoring Task Force Of The Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft Für Neuropsychopharmakologie Und Pharmakopsychiatrie. J Clin Psychiatry . 2020 May 19;81(3):19cs13169. doi: 10.4088/JCP.19cs13169. PMID: 32433836
200. Ponomareva OY, Redman B, Sayer MA, Wehring HJ, Vyas G, Richardson CM, Gold JM, Gorelick DA, Cihakova D, Talor MV, Hoag SW, Buchanan RW, Wang J, Chen S, Liu F, Wang JB, Kelly DL. L-Tetrahydropalmatine, a Novel Dopamine Antagonist, Fails to Improve Psychiatric Symptoms as Adjunctive Treatment for Schizophrenia. Schizophrenia Bulletin Open, 1,1, January 2020, sgaa026, https://doi.org/10.1093/schizbullopen/sgaa026
201. Dwyer KR, Andrea AM, Savage CLG, Orth RD, Shan L, Strauss GP, Adams HA, Kelly DL, Weiner E, Gold JM, McMahon RP, Carpenter WT, Buchanan RW, Blanchard JJ. A Randomized Clinical Trial of Oxytocin or Galantamine in Schizophrenia: Assessing the Impact on Behavioral, Lexical, and Self-Report Indicators of Social Affiliation Schizophr Bull Open. 2020 Jan; 1(1): sgaa001. Published online 2020 Aug 3. doi: 10.1093/schizbullopen/sgaa001 PMID: 32803156 PMCID: PMC7418868
202. Buchanan RW, Weiner E, Kelly DL, Gold JM, Chen S, Zaranski J, Blatt F, Wehring H, Carpenter WT. Anti-inflammatory Combination Therapy for the Treatment of Schizophrenia. J Clin Psychopharmacol. Sep/Oct 2020;40(5):444-450. doi: 10.1097/JCP.0000000000001253. PMID: 32796391
203. Shukla RP, Rapiera C, Glassman M, Liu F, Kelly DL, Ben-Yoav, Hadar. An integrated electrochemical microsystem for real-time treatment monitoring of clozapine in microliter volume samples from schizophrenia patients. Electrochemistry Communications, Oct 2020 https://doi.org/10.1016/j.elecom.2020.106850
204. Kelly DL, Spaderna M, Hodzic V, Nair S, Kitchen C, Werkheise AE, Powell MM, Liu F, Coppersmith G, Chen S, Resnik P. Blinded Clinical Ratings of Social Media Data are Correlated with In-Person Clinical Ratings in Participants Diagnosed with Either Depression,Schizophrenia, or Healthy Controls, Psychiatry Research Volume 294, December 2020, 113496 https://doi.org/10.1016/j.psychres.2020.113496
205. Kelly DL, Spaderna M, Hodzic V, Coppersmith G, Chen S, Resnik P. Can language use in social media help in the treatment of severe mental illness? Current Research in Psychiatry, 20211; 1(1): 1–4. doi: 10.46439/psychiatry.1.001. PMID: 34532718 PMCID: PMC8442995
206. Culpepper L., Vieta E., Kelly DL, Patel M., Szatmári B., Hankinson A., Earley W. Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. International Journal of Clinical Practice (in approval process)
207. Kelly DL, Kane, M, Fraser, C, Sayer, M, Grant-Beurmann, S, Liu, T, Gold, J, Notarengelo, F, Vyas, G, Richardson, C, August, S, Kotnana, B, Miller, J, Liu, F, Buchanan, RW. Prebiotic Treatment Increases Serum Butyrate in People with Schizophrenia: Results of an Open-Label Inpatient Pilot Clinical Trial. J Clin Psychopharmacol . 2021 Mar-Apr 01;41(2):200-202. doi: 10.1097/JCP.0000000000001364. PMID: 33587401
208. Friendshuh CR, Pocivavsek A, Demyonovich H, Rodriguez KM, Cihakova D, Talor MV, Richardson CM, Vyas G, Adams HA, Baratta AB, Fasano A, Cascella N, Feldman S, Liu F, Sayer M, Powell MM, Wehring HJ, Buchanan RW, Carpenter Jr WT, Eaton WW, Kelly DL. The Effects of a Gluten-Free Diet on Immune Markers and Kynurenic Acid Pathway Metabolites in Patients With Schizophrenia Positive for Antigliadin Antibodies Immunoglobulin G. J Clin Psychopharmacol . May/Jun 2020;40(3):317-319. doi: 10.1097/JCP.0000000000001197. PMID: 32332475 PMCID: PMC7185031
209. Buckley T, Kitchen C, Vyas G, Siegfried NA, Tefera E, Chen S, DiPaula BA, Kelly DL. Comparison of Novel Immunoassay With Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) for Therapeutic Drug Monitoring of Clozapine. Ther Drug Monit, 2020 Oct; 42 (5):771-777.
210. Kelly DL, Ponomareva OY, Mackowick M, Glassman M, Park J, Navarro-De La Vega M, Wehring HJ, Vyas G. Feasibility and patient-reported satisfaction using a novel point-of-care fingerstick method for monitoring absolute neutrophil count for clozapine. Ann Clin Psychiatry, 2021 May;33 (2):116-123.
211. Buchanan RW, Kelly DL. Strauss GP, Gold JM, Weiner E, Zaranski J, Chen S, Blatt F, Holden J, Granholm E. Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia. Journal of Clinical Psychopharmacology, 2021 May-Jun 01;41(3):236-243. doi: 10.1097/JCP.0000000000001397. PMID: 33783399
212. Goldstone LW, DiPaula BA, Werremeyer A, Botts S, Hepburn B, Liu HY, Duckworth K, Young AS, Kelly DL. The Role of Board Certified Psychiatric Pharmacists in Expanding Access to Care and Improving Patient Outcomes. Psychiatr Serv . 2021 May 4;appips202000066. doi: 10.1176/appi.ps.202000066. Online ahead of print. PMID: 33940946
213. H P E R S YM., Espy-Wilson C, Kelly DL, Kitchen C. Multimodal Approach For Assessing Neuromotor Coordination In Schizophrenia Using Convolutional Neural Networks. ICMI 2021
214. Redman B, Kitchen C, Johnson KW, Bezwada P, Kelly DL. Levels of prolactin and testosterone and associated sexual dysfunction and breast abnormalities in men with schizophrenia treated with antipsychotic medications. Journal of Psychiatric Research 2021, August [Epub ahead of print] doi. 10.1016/j.jpsychires.2021.08.022.in press
215. Zarzar TR, Kelly DL. Clozapine for Self-Injuruous and Aggressive Behaviors in Correctional Settings. Journal of Interrnational Corrections and Prisions Association, (Advancing Corrections), Edition #12-2021 pgs 108-117.
216. de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Anıl Yağcıoğlu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry. 2022 Mar;55(2):73-86. doi: 10.1055/a-1625-6388. Epub 2021 Dec 15. PMID: 34911124
217. Kelly DL, Buchanan RW. Can the current schizophrenia construct endure? Schizophr Res. 2022 Apr;242:64-66. doi: 10.1016/j.schres.2021.12.028. April 2022. PMID: 35067456
218. Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, Kane JM, Kelly DL, Laitman R, Lee J, MacCabe JH, Myles N, Nielsen J, Schulte PF, Taylor D, Verdoux H, Wheeler A, Freudenreich O. Clozapine and COVID-19: The authors respond. J Psychiatry Neurosci. 2020 Jul 1;45(4):E1-E2. doi: 10.1503/jpn.2045302.PMID: 32584530
219. Kim E, Zhao Z, Rzasa JR, Glassman M, Bentley WE, Chen S, Kelly DL, Payne GF. Association of acute psychosocial stress with oxidative stress: Evidence from serum analysis. Redox Biol. 2021 Nov;47:102138. doi: 10.1016/j.redox.2021.102138. Epub 2021 Sep 16.PMID: 34555595 PMCID: PMC8458980
220. Kelly DL, Claxton A, Bidollari I, Du Y. Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. Psychiatry Res. 2021 Aug;302:114030. doi: 10.1016/j.psychres.2021.114030.PMID: 34118485
221. Nallani MC, Powell MM., Pugh S, Kearns AM, Adams HA., Weiner E, Wehring HJ., McEvoy JP., Buckley PF., Liu F, Buchanan RW., Kelly DL. 25-Hydroxyvitamin D and metabolic-related laboratory values in women with schizophrenia and hyperprolactinemia. J Psychiatr Res . 2022 Apr 8;151:25-29. doi: 10.1016/j.jpsychires.2022.03.046. PMID: 35429802
222. Culpepper L, Vieta E, Kelly DL, Patel MD, Szatmári B, Hankinson A, Earley WR. Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. Neuropsychiatr Dis Treat. 2022;18:995-1011 https://doi.org/10.2147/NDT.S348143 PMID: 35591886 PMCID: PMC9112044
223. Zhao Z, Ozcan EE, VanArsdale E, Li J, Kim E, Sandler AD , Kelly DL, Bentley WE, Payne GF. Mediated Electrochemical Probing: A Systems-Level Tool for Redox Biology. ACS Chem Biol 2021 Jul 16;16(7):1099-1110. doi: 10.1021/acschembio.1c00267. PMID: 34156828
224. Cavaliere VS, Glassman M, DiPaula BA, Mackowick M, Wehring HJ, Liu F, Chen S, Park J, Love RC, Richardson CM, Vyas G, Kearns AM, Kelly DL. Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness. Schizophr Res 2022 May;243:163-169. doi: 10.1016/j.schres.2022.03.006. PMID: 35358857
225. Browne J, Harvey PD, Buchanan RW, Kelly DL, Strauss GP, Gold JM, Holden JL, Granholm E. A Longitudinal Examination of Real-World Sedentary Behavior in Adults with Schizophrenia-Spectrum Disorders in a Clinical Trial of Combined Oxytocin and Cognitive Behavioral Social Skills Training. Behav Sci (Basel) 2022 Feb 23;12(3):60. doi: 10.3390/bs12030060 PMID: 35323379 PMCID: PMC8945120
226. De Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Anıl Yağcıoğlu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, Müller DJ. Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry. 2022 Mar;55(2):e1. doi: 10.1055/a-1737-1527. Epub 2022 Jan 20 PMID: 35052001
227. Eaton WW, Rodriguez KM, Thomas MA, Johnson J, Talor MV, Dohan C, Bingham CO 3rd, Musci R, Roth K, Kelly DL, Cihakova D, Darrah E. Immunologic profiling in schizophrenia and rheumatoid arthritis. Psychiatry Res. 2022 Nov;317:114812. doi: 10.1016/j.psychres.2022.114812. Epub 2022 Aug 28. PMID: 36058039.
228. Sathyasaikumar KV, Notarangelo FM, Kelly DL, Rowland LM, Hare SM, Chen S, Mo C, Buchanan RW, Schwarcz R. Tryptophan Challenge in Healthy Controls and People with Schizophrenia: Acute Effects on Plasma Levels of Kynurenine, Kynurenic Acid and 5-Hydroxyindoleacetic Acid. Pharmaceuticals (Basel). 2022 Aug 15;15(8):1003. doi: 10.3390/ph15081003. PMID: 36015151; PMCID: PMC9416551.
229. Liu Y, Kim E, Motabar D, Zhao Z, Kelly DL, Bentley WE, Payne GF. Redox-enabled bio-electronics for information acquisition and transmission. IEEE Transactions on Molecular, Biological, and Multi-Scale Communications. eCF Paper Id: TMBMC-TPS-23-0014
230. Daniels EC, Eaton WW, Cihakova D, Talor MV , Lemke H , Mo C , Chen S, Notarangelo FM , Rodriguez KM , and Kelly DL. The relationship of peripheral inflammation with antibodies to gliadin (AGA IgG) in persons with schizophrenia. Schizophrenia Research; 256, (June 2023), Pages 50-51. https://doi.org/10.1016/j.schres.2023.02.027
231. Arrow K, Resnik P, Michel H, Kitchen C, Mo C, Chen S, Espy-Wilson C, Coppersmith G, Frazier C, Kelly DL. Evaluating the Use of Online Self-Report Questionnaires as Clinically Valid Mental Health Monitoring Tools in the Clinical Whitespace. Psychiatr Q. 2023 Jun;94(2):221-231. doi: 10.1007/s11126-023-10022-1. Epub 2023 May 5. PMID: 37145257; PMCID: PMC10160731
232. Hare SM, Adhikari BM, Mo C, Chen S, Wijtenburg SA, Seneviratne C, Kane-Gerard S, Sathyasaikumar KV, Notarangelo FM, Schwarcz R, Kelly DL, Rowland LM, Buchanan RW. Tryptophan challenge in individuals with schizophrenia and healthy controls: acute effects on circulating kynurenine and kynurenic acid, cognition and cerebral blood flow. Neuropsychopharmacology; 48, 2023 Apr 28, pages1594–1601. doi: 10.1038/s41386-023-01587-3. PMID: 37118058.
233. Kulaga SS, Wehring HJ, Demyanovoich HJ, Rubin L, Kelly DL. The hormonal effects of childhood trauma in adult women with and without schizophrenia. Schizophr Res. 2023 May;255:155-157. doi: 10.1016/j.schres.2023.03.043. PMID: 36989673.
234. Kulaga, S.S., Kelly, DL. Nutrition in the Treatment of Schizophrenia: Rationale and Review of Recent Evidence. Curr Behav Neurosci Rep 10, 49–57 (September 2023). https://doi.org/10.1007/s40473-023-00259-2

Dr. Kelly has been involved in numerous clinical trials for the treatment for schizophrenia and has been active in psychopharmacology research for the past 26 years. She has evaluated many novel medications and strategies in schizophrenia, most recently completing clinical trials with adjunctive minocycline, an antibiotic with anti-inflammatory properties and a clinical trial, the DAAMSEL trial, testing adjunct aripiprazole vs. placebo in premenopausal women with symptomatic hyperprolactinemia. She is conducting a confirmatory study to study a gluten free diet in patients who are positive for antigliadin antibodies, a possible biomarker for efficacy in this subpopulation. She also is studying the safety of clozapine in Benign Ethnic Neutropenia as well as a handful of other clinical trials. 

Dr. Kelly has been a proponent for more widespread use and currently is working on understanding barriers to current use, develop monitoring devices and study ways to better deliver treatment. She has a history in studying side effects and efficacy in numerous clinical studies with clozapine.

Honors and Awards

• NIMH New Investigator’s Award, awarded at the New Clinical Drug Evaluation Unit (NCDEU) meeting 1998
• Future Leaders in Psychiatry Award Selection, EmoryUniversity and Janssen Pharmaceutica 1999
• Young Investigator Award, International Congress of Schizophrenia Research 2001
• “Heroes in the Fight” Team Award awarded to the Treatment Research Program by NAMI, 12 other organizations and Eli Lilly 2008
• MM&M Award, Clinical Schizophrenia and Related Psychosis awarded for Best New Business Healthcare Publication; serve as founding Associate Editor 2008
• Best Medical Book Award, American Writers Association awarded for Pharmacotherapy Principles and Practice, 2^nd Edition. Authored Schizophrenia Chapter 2010
• Best Poster Award, Mid-Atlantic Micro-Nano Alliance Spring Workshop, 2015, Thomas Winkler, lead author and presenter 2015
• Honorable Mention Poster Award, Psychiatry Research Day, Spring 2015, Erica Davis, lead author and presenter. 2015
• President-Elect, College of Psychiatric and Neurologic Pharmacists 2016
• Professor with Tenure, University of Maryland School of Medicine 2016
• President, College of Psychiatric and Neurologic Pharmacists 2017
• Maltz Prize for Innovative & Promising Schizophrenia Research, Brain and Behavior Research Foundation 2017
• Fellow, American College of Neuropsychopharmacology 2018
• Past President, College of Psychiatric and Neurologic Pharmacists 2018
• NIMH R37 MERIT Award Grant for Successful Continuous Excellence in Research 2020
• Inaugural MPower Professorship Award. University of Maryland Strategic Partnership: MPowering the State, November 2021
• Outstanding Mentor Recognition Award at MSRD - at the 44th Annual Awards Program, November 2021
• Top 100 Women in Maryland 2023

Active Grants:

7/1/19-6/30/24             Deanna Kelly (Co-Investigator) PI:  R. Schwacz

“Kynurenic Acid and Cognitive Abnormalities in Schizophrenia”

5 P50 MH 103222 Total Direct Costs $$11,439,660.00

07/01/2017-05/31/2024 (NCE)             Deanna Kelly (PI)

“Confirmatory Double-Blind Placebo-Controlled Efficacy Trial of Gluten-Free Diet in a Subgroup of Persons with Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies”

NIMH #1R01 MH113617-01 Total Direct Costs $3,038,168.37

09/01/2018-08/31/2024           Deanna Kelly (Co-Investigator) PI: R.W. Buchanan

“Prebiotic Treatment in People with Schizophrenia”

4 R33 AT009990-03 Total award amount: $385,933.00

09/01/2018-08/31/2024           Deanna Kelly (Co-Investigator) PI: R.W. Buchanan

“Prebiotic Treatment in People with Schizophrenia”

4 R33 AT009990-03               Total award amount: $385,933.00

02/01/2020-11/30/2024 (NCE)           PI: Deanna Kelly

“A Randomized Controlled Trial of a Telementoring Program, Project ECHO, to Increase Clozapine Prescribing”

1R37MH121564 Total award amount: $3,078,526.00

12/01/2019-10/31/2024           Deanna Kelly (Co-Investigator) PI: C. Marano

“Translational Assessment of Brain Bioenergetic Function in Schizophrenia”

1RO1 MH121102 Total Award Amount: $2,955,782.00 

07/01/2021-06/30/2026           PI: Deanna Kelly

“4/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial”

R01MH120354-01 Total Award Amount: $386,250.00  

07/01/2021-06/30/2026           Deanna Kelly (Co-Investigator) PI: R.R. Girgis

“1/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial”

R01 MH 120317-01A1 Total Award Amount: $180,666.00

09/01/2021-08/31/2025           MPI: Deanna Kelly

“SCH: INT: Collaborative Research: Using Multi-Stage Learning to Prioritize Mental Health”

2124224 Total Award Amount: $315,565.00  

01/01/2022-12/31/2024           Deanna Kelly (Co-Investigator) PI: R.W. Buchanan

“Luteolin for the Treatment of Schizophrenia”

21T-002.a Total Award Amount: up to $534,981.00

Completed Grants:

1997-2004                       Deanna Kelly (Co-investigator) PI:  R. Conley

“New Antipsychotic Strategies: Quetiapine And Risperidone Vs. Fluphenazine In Treatment-Resistant Schizophrenia”

NIMH MH47311 Annual Direct Cost:  $321,508 Total Direct Cost:  $2,250,553

1998-2000                       Deanna Kelly (Co-principal investigator) PI:  R. Conley

“Determining The Effectiveness Of Novel Antipsychotic Agents”.

Stanley Medical Research Institute

Annual Direct Cost:  $49,235 Total Direct Cost:  $99,270

1999-2001                      Deanna Kelly (PI)

“Sexual Function and Prolactin Levels With Atypical Antipsychotics”

Stanley Medical Research Institute.

Annual Direct Cost:  $80,000 Total Direct Cost:  $116,000

1999-2000                      Deanna Kelly (PI)

“Clinical And Laboratory Parameters Associated With Weight Gain With Atypical Antipsychotic Treatment”

NIMH Intervention Research Center (IRC) pilot grant

Annual Direct Cost: $5,000 Total Direct Cost: $5,000

2000-2001                      Deanna Kelly (PI)

“An Evaluation of Clozapine Discontinuation In The Public Mental Health System In Maryland”

UMB DRIF Award

Annual Direct Cost:  $15,000 Total Direct Cost:  $15,000

2001-2004                      Deanna Kelly (Co-Investigator) PI: Matthew Nelson

“Atomoxetine as an Adjunct to Novel Antipsychotic Medications in the Treatment of Cognitive Deficits of Schizophrenia”

Stanley Medical Research Institute (01T-78)

Annual Direct Costs: $167,200 Total Direct Costs:  $234,393

2003-2005                      Deanna Kelly (PI)

“Cardiac-Related Mortality with Atypical Antipsychotics”

NIMH (R03 MH069871-02)

Annual Direct Cost:  $50,000 Total Direct Cost:  $150,000

2003-2008                       Deanna Kelly (Co-Investigator) PI:  W. Carpenter

“Advanced Center for Intervention and Services Research (ACISR)”

NIMH (P50 MH40279)

Annual Direct Cost: $240,000 Total Direct Cost:  $1,198,012

2003-2004                       Deanna Kelly (PI)

“Adjunctive Divalproex To Clozapine In Treatment-Resistant Schizophrenia”

Abbott Laboratories

Annual Direct Cost:  $12,360 Total Direct Cost:  $24,720

2004-2005                        Deanna Kelly (PI)

“The Utilization And Dosing Of Quetiapine In A Public Mental Health System”

AstraZeneca Pharmaceuticals

Annual Direct Cost: $17,450 Total Direct Cost:  $34,905

2004-2005                       Deanna Kelly (PI)

“Racial Differences in Clinical Variables, Treatment and Response to Clozapine in Clinical Trials vs. Real-World Treatment Settings”

NIMH P60 grant pilot project

Annual Direct Cost:  $23,988 Total Direct Cost:  $47,978

2005-2012                         Deanna Kelly (PI)

Residential Research Support Services

NIDA N01-DA-5-9909

Annual Direct Costs: Approximately $1,900,000 (Fee for services billed monthly, depending on level of productivity)

Total Direct Costs:  $13,074,633

2006-2009                        Deanna Kelly (Co-Investigator)  PI: R. Buchanan

“The Effects of the Cannabinoid-1 Receptor Antagonist, Rimonabant on Weight and Metabolic Risk Factors in People with Schizophrenia”

NIMH 1 R34 MH077839

Annual Direct Cost: $157,500 Total Direct Cost: $405,000

2006-2008                       Deanna Kelly (Coinvestigator no effort) PI:  J.C. Shim

“Varenicline for Neurocognition in Schizophrenia”

Stanley Medical Research Institute

Annual Direct Costs: $68,145 Total Direct Costs:  $136,289

2006-2010                       Deanna Kelly (Co-PI) PI: R. Buchanan

“Rasagiline in the treatment of persistent negative symptoms in schizophrenia”

Stanley Medical Research Institute (05T-705) with a 1 year extension

Annual Direct Costs: $85,580 Total Direct Costs:  $256,527

2007-2009                       Deanna Kelly (PI)

“Comorbid Substance Abuse & Long-Term Health Outcomes in Schizophrenia”

NIMH R03 MH076985

Annual Direct Costs: $50,000 Total Direct Costs:  $100,000

2007-2009                       Deanna Kelly (Co-Investigator) PI: J. Kreyenbuhl

“Schizophrenia PORT Treatment Recommendations Update 2008”

NIMH R13 MH080593

Annual Direct Cost:  $83,635 Total Direct Cost:  $167,270

2007-2008                       Deanna Kelly (Site Investigator) PI: Anil Malhotra

“Agranulocytosis Associated Clozapine”

Feinstein Institute Subaward from National Institutes of Health (NIH)

Annual Direct Costs: $ 12,000 Total Direct Costs:  $ 12,000

2008-2013                        Deanna Kelly (Co-Investigator) PI: W. Carpenter

“Center for Intervention Development and Applied Research (CIDAR).

Oxytocin And Galantamine For Negative Symptoms And Cognition In Schizophrenia”

NIMH P50 MH082999

Annual Direct Costs: $399,376 Total Direct Costs:  $1,999,879

2010-2012                        Deanna Kelly (Site PI) PI: Jeffrey Lieberman

“Clozapine Incuded Agranulocytosis Consortium (CIAC)”

Subaward on NIMH funded multisite study

Total award $20,000

2011-2013                        Deanna Kelly (Co-PI/mentor) PI:  K. Warren

“Effects of Intranasal Oxytocin on Satiety Signaling in People with Schizophrenia”

NARSAD Young Investigator Award (Grant #17699)

Annual Direct Costs:  $30,000 Total Direct Costs:  $60,000

2011-2014                       Deanna Kelly (PI)

“Adjunctive Minocycline in Clozapine Treatment Patients for Psychosis and Cognition”

NIMH 1R21MH091184-01A1

Annual Direct Costs: $150,000 Total Direct Costs:  $300,000

2012-2014                      Deanna Kelly (Mentor – no salary support) Julie Markham (PI)

Early Life Stress and Schizophrenia-Associated Phenotypes in Animal Models”

Brain & Behavior Research Foundation’s NARSAD Young Investigator Award

Annual Direct Costs: $30,000 Total Direct Costs:  $60,000

2013–2014                      Deanna Kelly (PI) (Multiple PI with Reza Ghodssi of UMCP)

“Biosensor Device for Clozapine Treatment Monitoring in Schizophrenia”

TEDCO Maryland Innovation Initiative Phase I 

Total Costs:$125,000

2004-2017                       Carpenter, William; Rowland, Laura (MPIs) Role: Mentor 

Multidisciplinary Schizophrenia Research Training (T32) (no salary support)

NIH #: 5 T32 MH067533-12

$276,371 annual costs

2014–2015                       Deanna Kelly (Mentor – no salary support) Kate Nugent (PI)

“Sex-Specific Outcomes after First Episode Psychosis: Relationship to Psychological versus Social Stress Response”

Brain & Behavior Research Foundation’s NARSAD Young Investigator Award

Annual Direct Costs: $30,000 Total Direct Costs: $60,000

2010-2015                       Deanna Kelly (Co-Investigator and Site PI for trial)  PI: J.B. Wang

“Development of I-THP as New Medication for Drug Addiction (DP1)”

NIDA X02 1DP1DA031401

Annual Direct Costs: $500,000 Total Direct Costs: $2,500,000

Site PI for the phase I clinical trial & oversee all aspects of the study.                     

2011-2016                      Deanna Kelly (PI)

“Adjunct Aripiprazole for Symptomatic Hyperprolactinemia in Female Schizophrenia”

NIH 1R01MH09007-01A1

Annual Direct Costs:  $200,000 Total Direct Cost:  $700,000

07/01/13–6/30/16            Deanna Kelly (Co-Investigator) Buchanan, Robert (PI)

“Oxytocin and Social Skills/Cognitive Behavioral Training in Schizophrenia”

NIMH 1R34MH100362-01 0.60 calendar months

Total Direct Costs $475,000 (3 years)

Co-Inv, help with design, recruitment, pharmacy issues and FDA IND issues.

09/01/15-08/31/16           Deanna Kelly(Co-Investigator) Himelhoch, Seth (PI)

Optimizing Smoking Cessation Treatments in Smokers Living with HIV/AIDS

1R56HL128148-01A128148-01

Direct Costs Year 1: $125,626

Co-Investigator, organize and oversee the pharmacy procedures, drug procurement and laboratory procedures in the study.

12/01/14-11/30/16          Deanna Kelly (Co-Investigator); Hahn, Britta (PI)

“Effects of Nicotine on Dependence-Related Associative Learning Processes”

NIDA 1R03 DA037509-01A1

Annual Direct Cost: $50,000

Co-Inv, assist with recruitment from the inpatient setting & study design.

2016-2017                        Buchanan, Robert (PI) Role: (Co-Investigator)

Chair’s Research Seed Funding Award, $25,000

Schizophrenia and the Gut Microbiome

6/01/12-11/30/16             Deanna Kelly (Co-Investigator) Buchanan, Robert (PI)

Anti-Inflammatory Combination Therapy for the Treatment of Schizophrenia

The Stanley Medical Research Institute Grant # 11T-002

Annual Direct Cost: $300,000 Total Direct Costs: $900,000

Co-Investigator & oversee all study procedures in the inpatient setting.

07/01/13–06/30/17          Deanna Kelly (PI)  (Multiple PI with William Eaton of JHU)

“Development for RCT of Gluten Free Diet in Gliadin-Positive Schizophrenia”

NIH 1R34MH100776-01 (Subaward with JHU)

Annual Direct Costs: $120,000          

03/24/16                          Deanna Kelly (PI)

Supplemental Funding from SMRI Grant #13-007 for entering harmonized and standardized data into the National Database for Clinical Trials related to mental illness (NDCT)

Total Direct Costs: $15,515

07/02/16-06/30/17            Deanna Kelly (PI)

Administrative Supplement

“Biomarker and Safety Study of Clozapine in Benign Ethnic Neutropenia” 

3R01MH102215-02S1

Direct Costs: $30,262

4/2016-3/2017                  Deanna Kelly (PI)

A Phase O Study to Assess Prolactin and Testosterone Levels and Associated Symptoms in Subjects with Schizophrenia XOMA, LLC $42,612

4/2017–3/2018                 Deanna Kelly (PI)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia ACP-103-034

$10,208 Direct Costs

01/01/15–12/31/17           Deanna Kelly (PI); Ghodssi, Reza (Co-PI)

“Microsystem Development for Clozapine Monitoring in Schizophrenia”

NIMH R56 Bridge Award to R01 MH105571-01

Direct Costs Year 1: $250,000

2016-2018                         Deanna Kelly; Resnik, Phillip (Co-PIs)

UMCP/UMB Innovation Seed Grant, $99,946

“Development of Computational Modeling to Identify Symptom Changes in Schizophrenia and Depression”

This project is seeking to initiate change in the monitoring of mental health conditions by making it possible to achieve minimally intrusive day to day monitoring via language analysis.

04/01/14–09/30/18            Deanna Kelly  (PI)

“Treatment of Schizophrenia with ltetrahydropalmatine (l-THP): a Novel Dopamine Antagonist with Anti-Inflammatory and Antiprotozoal Activity”

Stanley Medical Research Institute (SMRI), Grant# 13-007

Annual Direct Costs:$275,000 Total Direct Costs: $825,000

04/15/13 – 03/31/19    Kelly, Deanna (Mentor-no salary support) Heidi Wehring (PI)                     

“Tobacco Craving in Smokers with Schizophrenia”

NIDA 1K23 DA034034-01A1

Total Annual Direct Costs: $161,118 x 5 years

Primary mentor, assisted with career development, & all training aspects on design, conduct and dissemination.

 04/01/14 – 03/31/19    Kelly, Deanna (Co-Investigator, Project 4) Robert Schwarcz  (PI)                                                     

“Kynurenic Acid and Cognitive Abnormalities in Schizophrenia”

Silvio O. Conte Centers for Basic or Translational               

NIMH P50 MH103222 Annual Direct Costs: $1,456,033

Co-Investigator on project 4, oversee the study procedures and supervise clinical staff working on the protocol.

6/2017-5/31/2019        Ben-Yoav, Hadar PI; Kelly, Deanna L.: Role – Mentor, No Salary Support

Real-Time Monitoring of Clozapine Levels in Capillary Blood

Brain & Behavior Research Foundation (NARSAD Grant # 74804)

Total Costs: $70,000

07/01/12 - 06/30/20     Deanna Kelly (Co-investigator) PI: Raymond C. Love

State of Maryland Medicaid Contract, Antipsychotic Utilization Review                  

Annual Direct Costs: $699,890. This is up for possible renewal each year.       

04/01/15 – 03/31/20      Deanna Kelly (PI)

“Biomarker and Safety Study of Clozapine in Benign Ethnic Neutropenia” 

NIMH R01 MH102215 Direct Costs Year 1: $705,631

12/15/16-11/30/20         Deanna Kelly (PI) Role: (PI), MPI: Seth Himelhoch

“Optimizing Smoking Cessation Treatments in Smokers Living with HIV/AIDS”

NIMH #: 1R01HL136253-01 Total Direct Costs: $513,202 (annual)

7/1/2017 – 6/30/2021     Carpenter, William; Rowland, Laura (MPIs) Role: Mentor (no salary support)

Multidisciplinary Schizophrenia Research Training (T32)

NIH #: 5 T32 MH067533-12

$257,371 Direct Costs current year ($1,399,091 total direct costs)

07/01/17-06/30/20          Deanna Kelly (PI)

Administrative Supplement

“Biomarker and Safety Study of Clozapine in Benign Ethnic Neutropenia” 

3R01MH102215-02S2 Direct Costs: $78,834

02/05/18-02/04/21          Deanna Kelly (Co-Investigator)

"Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People with Schizophrenia"

Total costs: $359,285

09/15/18-09/14/23          Deanna Kelly (Co-Investigator)

“Prebiotic Treatment in People with Schizophrenia”

R61AT009990-01

NCCIH Natural Product Phase 1-11a Clinical Trial Phased Innovation Award (R61/R33)

$1,775,771.72 (Total Costs All Years) Direct Costs Year 1: $308,878.00

Media Links and Interviews

1. Kelly DL, Conley RR, Love RC. The emerging dilemma: affordable quality care for  schizophrenia. Use of new antipsychotics. Medicaid Update 2002;17(2),
   
   www.health.state.ny.us/nysdoh/mancare/omm/2002/feb2002.htm#care.
   
   
2. McCausland C. Real world training for the next generation: residents. Capsule: University of Maryland School of Pharmacy Magazine. Summer 2010.
   
   
3. Warren KW, Kelly DL. Brief Psychotic Disorder. British Medical Journal Online 2011 present.
   
   https://online.epocrates.com/u/29111118/Brief+psychotic+disorder.
   
   
4. Worchester S. Oxytocin May Aid Schizophrenia Patients.  Clinical Psychiatry News 2012; 40(8),
   
   www.clinicalpsychiatrynews.com
   
   
5. Arehart-Treichel J. Will Antibiotic Fulfull Its Psychosis-Fighting Promise?  Psychiatric News 2012; 47(15),
   
   www.pschnews.org
   
   
6. Arehart-Treichel J. Metformin May Help Combat Antipsychotic-Induced Weight Gain. Psychiatry Online Clinical and Research News 2014;
   
   http://psychnews.psychiatryonline.org/newsarticle.aspx?articleid=1866046
   
   
7. University of Maryland Department of Psychiatry Video at the American Psychiatric Association Meeting 2014
   
   https://vimeo.com/93338481.
   
   
8. Velasquez-Manoff M. Can Celiac Disease Affect the Brain? New York Times October 11, 1014.
   
   http://nyti.ms/1srryi3
   
   
9. Moran M. Clozapine Monotherapy More Cost-Effective than Antipsychotic Polypharmacy, Study Shows. Psychiatric News October 28, 2014
   
   http://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2014.11b10
   
   
10. Moran M. Why won’t clinicians use clozapine despite proven superiority? Psychiatric News 2015;50(17),
    
    www.psychnews.org.
    
    
11. Harrison P. Oxytocin Shows no Effect in Schizophrenia. Medscape Multispeciality Medical News. September 2, 2015
    
    http://www.medscape.com/viewarticle/850411
    
    
12. Science Daily. January 18, 2017. Changes in blood-brain barrier, intestinal permeability found in individuals with autism.
    
    https://www.sciencedaily.com/releases/2017/01/170118145937.htm
    
    
13. Phys Org. February 9, 2017. Technique to measure oxidative stress in blood samples offers potential aid in schizophrenia diagnosis.
    
    https://phys.org/news/2017-02-technique-oxidative-stress-blood-samples.html
    
    
14. University of Maryland News. UMD Researchers Make Strides in Schizophrenia Diagnosis Research.
    
    http://eng.umd.edu/news/story/umd-researchers-make-strides-in-schizophrenia-diagnosis-research
    
    
15. Moran M.  Aripiprazole may reduce some side effects of antipsychotics in women.  Psychiatric News.  April 21, 2017.
    
    http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2017.pp4b2
    
    
16. Psychiatric News Alert.  White paper offers recommendations for expanding clozapine use.
    
    http://alert.psychnews.org/2017/04/white-paper-offers-recommendations-for.html
    
    
17. University of Maryland School of Pharmacy News Center.  Prestigious Award Honors UM Pharmacist's Innovative Research.
    
    http://news.pharmacy.umaryland.edu/prestigious-award-honors-um-pharmacists-innovative-research/
    
    
18. Press Release:  Brain & Behavior Research Foundation Honors Nine Scientists for Outstanding Achievements in Psychiatric Research at 30th Annual Dinner.
    
    https://www.bbrfoundation.org/content/brain-behavior-research-foundation-honors-nine-scientists-outstanding-achievements
    
    
19. You Tube: The Brain & Behavior Research Foundation awarded the Maltz Prize for Innovative & Promising Schizophrenia Research to Deanna L. Kelly, Pharm.D., BCPP, of the University of Maryland School of Medicine.
    
    https://www.youtube.com/watch?v=y-9lOpPUdg0
    
    
20. Brain and Behavior Research Foundation.  Announcement of the Maltz Prize for Innovative and Promising Schizophrenia Research
    
    https://www.bbrfoundation.org/about/people/deanna-l-kelly-pharmd-bcpp
    
    
21. University of Maryland School of Medicine Press Release
    
    http://somvweb.som.umaryland.edu/absolutenm/templates/?a=3669
    
    
22. Facebook posts for Maltz Prize for Innovative & Promising Schizophrenia Research
    
    https://www.facebook.com/UMSOP/posts/10155673810130218
    
    https://www.facebook.com/cpnp.org/photos/pb.313227992071041.-2207520000.1514683323./1582528075141020/?type=3&theater
    
    
23. Love, S.  A Common Food Brought on this Women’s Psychoses. Interview in article, March 2018.
    
    https://tonic.vice.com/en_us/article/ywq7nj/the-strange-case-of-gluten-induced-psychosis
    
    
24. UMB Researchers Revolutionize Oxidative Stress Diagnostics. Nominated for Invention of the Year 2017
    
    https://research.umd.edu/news/news_story.php?id=11153
    
    
25. Alumna wins  Maltz Prize for Innovative and Promising Schizophrenia Research. Duquesne University News
    
    http://www.duq.edu/academics/schools/pharmacy/news/alumna-wins-maltz-prize-for-innovative-and-promising-schizophrenia-research
    
    
26. Psychiatry Advisor: Adjunctive Aripiprazole Lowers Prolactin Levels in Women With Psychosis, July 2018.
    
    https://www.psychiatryadvisor.com/schizophrenia-and-psychoses/adjunctive-aripiprazole-effective-in-lowering-prolactin-levels-in-women-with-psychosis/article/779343/
    
    
27. American Psychiatric Association: Adjunctive Aripiprazole May Reduce Prolactin-Related Side Effects of Antipsychotics in Women, August 2018
    
    http://alert.psychnews.org/2018/08/adjunctive-aripiprazole-may-reduce.html
    
    
28. Psychiatric News Alert.  More African Americans With Schizophrenia Could Receive Clozapine Despite Lower White Blood Cell Counts.
    
    http://alert.psychnews.org/2018/10/more-african-americans-with.html
29. Psychiatric News: More Minority Patients May Be Able to Safely Use Clozapine, October 2018

    https://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2018.pp10a3

30. University of Maryland School of Medicine: Researchers awarded $1.78 million grant to study Brain-to-Gut Connection in Schizophrenia.

    https://www.eurekalert.org/pub_releases/2018-12/uoms-ra120418.php

31. Morrison J. UMSOM/UMSOP Researchers Awarded $1.78 Million Grant to Study Brain-To-Gut Connection in Schizophrenia.

    http://www.medschool.umaryland.edu/news/2018/UMSOMUMSOP-Researchers-Awarded-178-Million-Grant-to-Study-Brain-To-Gut-Connection-in-Schizophrenia.html

32. Amersbach G. New Research Seeks the Impact of Gut Bacteria in Schizophrenia. A University of Maryland Research Study Investigates the Role of Prebiotin on Cognitive Function.

    https://www.prebiotin.com/new-research-seeks-the-impact-of-gut-bacteria-in-schizophrenia/

33. National Association of State Mental Health Program Directors (NASMHPD): New SAMHSA-Sponsored Clinical Support System for Persons with SMI (SMI Advisor) includes Clozapine Center of Excellence Assembled by NASMHPD, March 1, 2019 (Vol.5, No. 9).

    https://www.nasmhpd.org/sites/default/files/March-1-2019_NASMHPD_Weekly_Update.pdf

34. Collins, TR. MDedge, Clinical Psychiatry News: Interest renewed in targeting gluten in schizophrenia, April 12, 2019.

    https://www.mdedge.com/psychiatry/article/198818/schizophrenia-other-psychotic-disorders/interest-renewed-targeting-gluten

35. Lowry, F. Medscape Medical News: More Evidence Schizophrenia Combo Therapy Blunts Weight Gain, April 15, 2019.

    https://www.medscape.com/viewarticle/911797#vp_2

36. Lowry, F. Medscape Medical News: Exercise Cuts Brain Inflammation in First-Episode Psychosis, April 16, 2019.

    https://www.medscape.com/viewarticle/911861?src=rss

37. Lowry, F. Medscape Medical News: Gluten-Free Diet May Ease Schizophrenia Symptoms, April 15, 2019.

    https://www.medscape.com/viewarticle/911794

38. Waffle, V. Gluten-Free Living: Gluten-Free Diet Helps Some With Schizophrenia in Pilot Study, April 19, 2019.

    https://www.glutenfreeliving.com/blog/gluten-free-diet-helps-some-with-schizophrenia-in-pilot-study/

39. Castillo, K. Media Planet: The Brain Benefits of Adding Prebiotic Fiber to Your Diet, June 28, 2019.

    https://www.futureofpersonalhealth.com/digestive-wellness/the-brain-benefits-of-adding-prebiotic-fiber-to-your-diet/

40. Love, S. Vice Media: The Psychiatric ‘Wonder Drug’ That Almost No One is Using, August 5, 2019.

    https://www.vice.com/en_us/article/qvgdj3/the-psychiatric-wonder-drug-that-almost-no-one-is-using

41. Landau, MD. Everyday Health, Inc.: Does Yoga Belong in a Schizophrenia Treatment Plan?, November 4, 2019.

    https://www.everydayhealth.com/schizophrenia/does-yoga-belong-in-a-schizophrenia-treatment-plan/

42. Psychiatric News: Women With Schizophrenia Only Half as Likely to Receive Mammograms, January 2020.

    https://psychnews.psychiatryonline.org/doi/10.1176/appi.pn.2020.1a17

43. Woman’s Day: Mental Health Issues Are the Menopausal Side Affect We're Not Talking About, January 27, 2020.

    https://www.womansday.com/health-fitness/a30515712/how-menopause-affects-mental-health/

44. NAMI Advocate: Reflecting on Our Grassroots, Winter 2019. Ask Dr. Ken with Dr. Ken Duckworth, M.D.

    http://www.namiwa.org/images/pdfs/2019Winter-NAMIAdvocate-web.pdf

45. Ives, J. News-Medical.net: News Medical Life Sciences: UMB and UMD fund cross-campus research projects, April 23, 2020.

    https://www.news-medical.net/news/20200423/UMB-and-UMD-fund-cross-campus-research-projects.aspx

46. University of Maryland School of Medicine: Researchers Launch Study to Improve Prescribing of Clozapine for More Effective Management of Schizophrenia, May 15, 2020. https://www.medschool.umaryland.edu/news/2020/Researchers-Launch-Study-to-Improve-Prescribing-of-Clozapine-for-More-Effective-Management-of-Schizophrenia.html
47. Robert E. Fischell Institute for Biomedical Devices: Team Competes for $10K to Support Oxidative Stress Research, September 18, 2020.

    https://fischellinstitute.umd.edu/news/story/team-competes-for-10k-to-support-oxidative-stress-research

    https://www.youtube.com/watch?time_continue=3&v=wRpKIoEWDNI&feature=emb_title
48. Med-Tech Innovation News: Researchers develop novel method of monitoring blood levels from antipsychotic drug, February 16, 2021.

    https://www.med-technews.com/news/latest-medtech-news/researchers-develop-method-monitoring-blood-levels-from-ant/

49. CME Outfitters Snack: Long-acting Injectables in Schizophrenia: An Evidence-Based Strategy to Get Your Patients to Remission and Recovery, October 2021.

    https://onlinexperiences.com/Launch/Event/ShowKey=171000

50. MPower Professor: University of Maryland Strategic Partnership: MPowering the State (MPower) recognizes, incentivizes and fosters collaborations between faculty in Baltimore and College Park.

    https://umdrightnow.umd.edu/university-of-maryland-strategic-partnership-announces-mpower-professorships

51. MPower Professor: A. James Clark School of Engineering, Frequent research collaborator Deanna Kelly named 'MPower Professor'

    https://ece.umd.edu/news/story/frequent-research-collaborator-deanna-kelly-named-mpower-professor

52. “MPowering” Collaboration and Innovation December 15, 2021 University of Maryland Strategic Partnership: MPowering the State

    https://www.umaryland.edu/news/archived-news/december-2021/mpowering-collaboration-and-innovation-.php

53. Sequoia Capital: The Listeners - For Deepika Bodapati and Tanay Tandon of Athelas, paying attention is a superpower. https://www.sequoiacap.com/article/deepika-bodapati-and-tanay-tandon-spotlight-athelas/
54. com; Schizophrenia: Is the FDA Hindering the Most Effective Med?, May 24, 2023 https://www.webmd.com/schizophrenia/features/schizophrenia-fda-hindering-clozapine?src=rss_public

Administrative Services

Institutional Services: 

2003-2011                  Schizophrenia Patient Outcomes Research Team (PORT)

Monthly literature searches and database entry, assisted with grant writing, assisted with thought leader meeting, wrote 5 recommendations, assisted with manuscript

2004-2008                  University of Maryland Mental Health Disparities Steering Committee

Committee member representing MPRC, wrote 2 pilot grants and authored two publications, organized disparities speakers and symposia, assisted in other projects, education and outreach

2006-present             T32 MPRC Fellowship Committee

Review and interview fellowship candidates, meet regularly to review progress, assist with grant writing and fellowship program

2007-present             Chair, Junior Faculty Mentoring Committee

Developed formal mentoring program and documents including program description, roadmap, mentorship materials, organize annual mentorship meetings and Department of Psychiatry mentorship programmed modeled after this program

2008-2009                  Acting Chief and Director of the Treatment Research Program, (MPRC), UMSOM

2008-present             Vice Chair, Department of Health and Mental Hygiene Institutional Review Board.

Participate in monthly IRB reviews and meetings and function as Chair in her absence.

2008                            Successfully negotiated a smoking exemption and associated policies and procedures with Spring Grove Hospital to permit smoking in designated areas of MPRC for continued studies in dual diagnosis research.

2008-2012                  PI/PO NIDA Research Contract Committee Chair

Developed and maintained infrastructure and oversight of multimillion dollar contract. Committee meets twice monthly to discuss protocol progress, regulatory issues, budgets and personnel on 30 protocols

2009-present              Chief and Director of the Treatment Research Program, MPRC, UMSOM.

Administratively coordinate inpatient research program with approximately 13 research staff and 9 clinical staff.

2009-present              Successfully initiated and negotiated the MOU, approval and opening of the Brief Stay Unit, a unit at MPRC dedicated to short overnight stays for Clinical Research.

2009                             Department of Psychiatry 60^th Anniversary Gala Committee

MPRC liaison monthly meetings for 6 months

2009-present              Administratively direct the Treatment Research Program. This program consists of a 24 bed inpatient program, 13 clinical staff and 12 research staff

2010-present              Co-Direct the Antipsychotic Pharmacy Review Program for the State of Maryland Department of Health and Mental Hygiene and the Medicaid pharmacy program.

2010-2012                   UMSOM Multidisciplinary Advisory Committee (MAC) for K12 Training Awards. Monthly meeting to discuss and review awardees in the SOM

2010                            Successfully negotiated a MOU between the University of Maryland IRB and the Department of Health and Mental Hygiene IRB for reliance on protocols

2011                            Organizer of 2011 speakers for series entitled, “Biological Psychiatry of Immune and Inflammatory Mechanisms of Schizophrenia.”  Organized and invited outside speakers for the series.

2011-present               Director, Brief Stay Unit, MPRC, UMSOM. Developed and direct 3 bedroom short stay unit for early phase studies.

2011-present               UMB Department of Psychiatry Appointment, Promotions and Tenure (APT) Committee

2012-present               Administrative support including infrastructure, space and allocate personnel to the Maryland Peer to Peer Antipsychotic Review Project. Oversee space and infrastructure issues related to the pharmacy department of 6 clinical pharmacists.

2012-present               Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) Internal Advisory Committee member, UMB

2013-2016                    Videoconferencing committee, Department of Psychiatry

2013-present              Coordinator, Psychiatry Resident Electives at MPRC

2013-present              Silvio O. Conte Summer Scholar Selection and Review Committee

2015-present              Maryland Brain Collection Steering Committee

2016-present              Full faculty member to UMSOM council

2019                          American Society of Clinical Psychopharmacology (ASCP), Nina Schooler Early Career Research Award Committee

2019-present               Member, UMSOM Research Affairs Advisory Committee (RAAC)

2021-present               Dept of Psychiatry-Department Initiatives and Social Justice Planning Committee/Diversity Committee.

2021-present               Research Steering Committee

2021-present               Research Affairs Advisory Committee (RAAC)

2021-present               MPRC NAMI Creativity Connects/Walks Committee

2021-present               NAMI Steering Committee

2021-present               MPRC DEI Committee

2022-present               Acting Director, MPRC, UMSOM

2022-present               AAPP Design Task Force Committee

2022-present               Medscape Steering Committee

National and International Service:

2002                            NIMH Pharmacoeconomics Advisory Board      

2004-2006                 Treasurer and Board of Directors, College of Psychiatric and Neurologic Pharmacists (CPNP)

2004-2009                 Department of VA Mental Health and Behavioral Sciences Review Committee for National VA merit grants

2004                            Elected Treasurer and Board Member in the College of Psychiatric and Neurologic Pharmacists (CPNP)

2005                            Canadian Institutes of Health Research grant reviewer

2005-2008                 Member, Membership Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

2005-2008                 Member, Finance Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

2005-2008                 Member, Web Task Force, College of Psychiatric and Neurologic Pharmacists (CPNP)

2005-present           Editorial Board Member, Schizophrenia Bulletin

2006                           Health Care Efficiency Research Programme (Netherlands) grant reviewer

2006                           Thrasher Research Fund grant reviewer

2006                           Textbook reviewer for Burger’s Sixth Edition Medicinal Chemistry and Drug Discovery

2006-2009                  Member, Communications Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

2007                            Member, Awards Committee, College of Psychiatric and Neurologic Pharmacists (CPNP)

2007                            Mission trip to Ecuador, developed library at Spanish speaking school

2011-2017                 Program Committee, CPNP

2011-2015                 Grant Reviewer, United Kingdom, National Institute for the Health Research and Policy Research Programme

2011-2013                 NIH Special Emphasis Panel/Scientific Review Group ZRG1 EMNR-R (55)

2012-2013                 NIDA IRP Independent Monitoring Board

2013                            NIH workshop (NIMH, NIDA, NCI) for Smoking Cessation in Schizophrenia

2013-2014                 Program Chair, CPNP Annual Meeting, 2014

2013-2017                 Data Safety Monitoring Board, NIH, Intramural Research Program

2016-present           Government Affairs committee, CPNP

2016-present           National Association of State Mental Health Programs Director (NASMHPD) clozapine white paper task force

2016-present           Food and Drug Association (FDA) network of experts

2017                           Substance Abuse and Mental Health Services Administration (SAMHSA) taskforce for Behavioral Health Pharmacist integration in Psychiatry

2017                           Substance Abuse and Mental Health Services Administration (SAMHSA) taskforce for Clozapine Centers of Excellence

July 2017                     NIMHHD U-Award review committee (ZMD1)

2018-present               Hillside Hospital Data Safety Monitoring Board

2018-present               ASCP Membership committee and Nina Schooler Early Career Research Award Committee

2018-present               CSS SMI Clozapine Content Expert

2019-present               Professional Affairs Committee, AAPP

2020                            NIMH ZMH1 ERB-D (04) S - Early Phase Clinical Trials – Pharma/Device Reviewe Committee

2020-present               Data Safety Monitoring Board, Optimizing Smoking Cessation Treatments in Smokers Living with HIV/AIDS                                              Nairobi, Kenya, R01 CA225419 01A1

2021                             Data Safety Monitoring Board, Alcohol Cessation Interventions For People Living with Human                                                                     Immunodeficiency Virus (PLHIV) in Nairobi, Kenya: A Nested Study.

Local Service:

1996-present             Volunteer, Treatment Research Program/Spring Grove Hospital Talent Show and Family Events

2005-present             Maryland NAMI fundraisers, walks, charity events

2005-present             Volunteer, CentralYorkSchool District

2006-present             Community Service projects through LivingWordCommunityChurch

2008-present             Participant and mentor in the Atholton High School Gifted program

2008-2012                  Volunteer, SpringGroveHospital 5K event

2011-2013                  Board Member, Typical Life Corporation, Inc.

2015-2017               State of Maryland Behavioral Health Administration Clozapine Task Force

Journal Editor and Review:

1998-present             American Journal of Psychiatry (2x/yr), BioMed Central (BMC) Psychiatry (6x/yr), CNS Drugs (1x/yr), Journal of Clinical Psychiatry (4x/yr), Journal of Clinical Psychopharmacology (1-2x/yr), Journal of Psychiatric Research (1-  2x/yr), Journal of Nervous and Mental Disease (1x/yr), Progress in Neuro-Psychopharmacology and Biological Psychiatry (1-2x/yr), Psychiatric Services (3x/yr), Psychiatry Research (3x/yr), Schizophrenia Research (4x/yr), Schizophrenia Bulletin (4-5x/yr)

1999-2000                 Journal of Post Graduate Medicine, Israeli Journal of Psychiatry, Journal of Child and Adolescent Psychopharmacology

2000-2002                 Acta Pharmacologica Sinica, Indian Journal of Medical Sciences, Journal of Pediatric Nephrology, European Archives of Psychiatry and Clinical Neuroscience

2003-2004                 Advances in Schizophrenia and Clinical Psychiatry, Archives of Medical Research, Expert Review Neurotherapeutics, Journal of Sexual Medicine

2005-2006                 Disease Management and Health Outcomes, Expert Review of Pharmacoeconomics and Outcomes Research, European Psychiatry

2007-2008                 Pharmacopsychiatry, Women & Health

2009                           Journal of Psychopharmacology, Human Psychopharmacology: Clinical and Experimental, Journal of the American Psychiatric Nurses Association

2010                           Acta Psychiatrica Scandinavica, Psychoneuroendocrinology, Archives of General Psychiatry

2011                           Neuropsychopharmacology

2016                           Journal of Forensic Psychiatry and Psychology

Editor:

2006-2019                  Associate Editor, Clinical Schizophrenia and Related Psychosis (40 per year)

2006-2019                  Editorial Board Member, Clinical Schizophrenia and Related Psychosis

2008-present               Associate Guest Editor, Schizophrenia Bulletin (5 per year)

2009-present               Associate Editor, BMC-Psychiatry (6 per year)

2011-present               Editorial Board Member, Current Psychopharmacology (2 per year)

2019-present               Editorial Board Member, Therapeutic Advances in Psychopharmacology

The Maltz Prize for Innovative & Promising Schizophrenia Research was awarded to Deanna L. Kelly, Pharm.D., BCPP at the University of Maryland School of Medicine.

Please visit Brain & Behavior Research Foundation to learn more.